Q4 2024 DarioHealth Corp Earnings Call

Following the presentation, we will conduct a question and answer session.

Yeah.

Unknown Executive: Good morning, ladies and gentlemen, and welcome to the DarioHealth fourth quarter 2024 results conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator.

Speaker Change: Good morning, ladies and gentlemen, and welcome to the <unk>.

At any time during this call you required immediate assistance. Please press star zero for the operator. This call is being recorded on Monday March 10, 2025, I would now like to turn the conference over to Cat Perilla Investor Relations manager at Dario. Please go ahead.

Speaker Change: Our real House fourth quarter 2024 results conference call at this time all lines are in a listen only mode. Following the presentation. We will conduct a question and answer session. If at any time during this call. The required immediate assistance. Please press star zero for the operator. This call is being recorded on Monday March 10, 2025, I would now like.

Unknown Executive: This call is being recorded on Monday, March 10, 2025.

Speaker Change: Thank you operator, and good morning, everyone. Thank you for joining us today for a discussion of <unk> fourth quarter and full year 2024 financial result.

Kat Parrella: I would now like to turn the conference over to Kat Parrella, Investor Relations Manager at DarioHealth. Please go ahead. Thank you, Operator, and good morning, everyone. Thank you for joining us today for a discussion of DarioHealth's fourth quarter and full year 2024 financial results.

Cat Perilla: To turn the conference over to Cat Perilla Investor Relations manager at Dario. Please go ahead.

Speaker Change: Leading the call today will be Erez Raphael Chief Executive Officer of Dario helps.

Speaker Change: Thank you operator, and good morning, everyone. Thank you for joining us today for a discussion of <unk> fourth quarter and full year 'twenty 'twenty four financial results.

Steven Nelson: He joined by Steven Nelson Chief Commercial Officer.

Steven Nelson: An audio recording and webcast replay for today's call will also be available online as detailed in the press release invite for this call for.

Unknown Executive: Leading the call today will be Erez Raphael, Chief Executive Officer of DarioHealth. He'll be joined by Steven Nelson, Chief Commercial Officer.

Erez Raphael: Leading the call today will be Erez Raphael Chief Executive Officer will be joined by Steven Nelson Chief Commercial officer.

Steven Nelson: For the benefit of those who maybe listening to the replay or archived webcast. This call is being held on Monday March 10 2025.

Unknown Executive: And audio recording and webcast replay for today's call will also be available online as detailed in the press release invite for this call. For the benefit of those who may be listening to the replay or archived webcast, this call is being held on Monday, March 10, 2025.

Erez Raphael: An audio recording and webcast replay for today's call will also be available online as detailed in the press release invite for this call.

Steven Nelson: This morning, we issued a press release announcing our financial results for the fourth quarter of 2024.

Speaker Change: For the benefit of those who maybe listening to the replay or archived webcast. This call is being held on Monday March 10 2025.

Steven Nelson: A copy of the release can be found on the Investor Relations page of Dario helps website.

Steven Nelson: Actual events or results may differ materially from those projected as a result of changing market trends.

Unknown Executive: This morning we issued a press release announcing our financial results for the fourth quarter of 2024. A copy of the release can be found on the investor relations page of DarioHealth's website.

Speaker Change: This morning, we issued a press release announcing our financial results for the fourth quarter of 2024.

Steven Nelson: Didn't ends or the competitive nature of Dario helps industry.

Speaker Change: A copy of the release can be found on the Investor Relations page of website.

Steven Nelson: Such forward looking statements and their implications may involve known and unknown risks uncertainties and other factors that may cause actual results or performance to differ materially from those projected.

Speaker Change: Website.

Unknown Executive: Actual events or results may differ materially from those projected as a result of changing market trends, reduced demand, or the competitive nature of DarioHealth's industry. Such forward-looking statements and their implications may involve known and unknown risks, uncertainties, and other factors that may cause actual results or performance to differ materially from those projected. The forward-looking statements discussed on this call are subject to other risks and uncertainties, including those discussed in the risk factors section and elsewhere in the company's fourth quarter 2024 quarterly report on Form 10-K.

Speaker Change: Actual events or results may differ materially from those projected as a result of changing market trends.

Speaker Change: Is demand or the competitive nature of.

Steven Nelson: The forward looking statements discussed on this call are subject to other risks and uncertainties, including those discussed in the risk factors section and elsewhere in the company's fourth quarter 2024, our quarterly report on Form 10-K.

Speaker Change: Industry.

Speaker Change: Such forward looking statements and their implications may involve known and unknown risks uncertainties and other factors that may cause actual results or performance to differ materially from those projected.

Steven Nelson: Additional information concerning factors that could cause results to differ materially from our forward looking statements are described in greater detail in the company's press release issued this morning and in the Companys other filings with the SEC.

Speaker Change: The forward looking statements discussed on this call are subject to other risks and uncertainties, including those discussed in the risk factors section and elsewhere in the company's fourth quarter 2024 quarterly report on Form 10-K.

Steven Nelson: In addition, certain non-GAAP financial measures may be discussed during this call. These non-GAAP measures are used by management to make strategic decisions forecast future results and evaluate the companys current performance.

Unknown Executive: Additional information concerning factors that could cause results to differ materially from our forward-looking statements are described in greater detail in the company's press release issued this morning and in the company's other filings with the SEC.

Speaker Change: Additional information concerning factors that could cause results to differ materially from our forward looking statements are described in greater detail in the company's press release issued this morning and in the company's other filings with the SEC.

Steven Nelson: Management believes the presentation of these non-GAAP financial measures is useful for investors understanding and assessment of the Companys ongoing core operations and prospects for the future of.

Unknown Executive: In addition, certain non-GAAP financial measures may be discussed during this call. These non-GAAP measures are used by management to make strategic decisions, forecast future results, and evaluate the company's current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors understanding and assessment of the company's ongoing core operations and prospects for the future. A reconciliation of these non-gap measures to the most comparable gap measures is included in this morning's press release.

Speaker Change: In addition, certain non-GAAP financial measures may be discussed during this call. These non-GAAP measures are used by management to make strategic decisions forecast future results and evaluate the company's current performance.

Steven Nelson: A reconciliation of these non-GAAP measures to the most comparable GAAP measures is included in this morning's press release with that I'll hand, it over to Erez Raphael CEO Dr. Johan.

Speaker Change: Management believes the presentation of these non-GAAP financial measures is useful for investors understanding and assessment of the company's ongoing core operations and prospects for the future.

Speaker Change: Thank you Scott.

Speaker Change: Hey, guys everyone.

Speaker Change: Thank you for joining our call this morning.

Speaker Change: A reconciliation of these non-GAAP measures to the most comparable GAAP measure is included in this morning's press release.

Speaker Change: The past year.

Speaker Change: <unk> has undergone a transformation of evolving into a leading healthcare technology company operating on the fast like more than.

Erez Raphael: With that, I'll hand it over to Erez Raphael, CEO of DarioHealth. Thank you, Kat. Good morning, everyone, and thank you for joining our call.

Erez Raphael: With that I'll hand, it over to Erez Raphael CEO of <unk> health.

Speaker Change: Thank you Scott Good morning, guys, we want.

Erez Raphael: You all joining our call this morning.

Speaker Change: These simple mission has solidified <unk> position as a premium platform and debate a BDC market expanding sales to employers health. Thanks.

Erez Raphael: Over the past year, DarioHealth has undergone a transformational shift, evolving into a leading healthcare technology company operating under a SaaS-like model. Its evolution has solidified Dario's position as a premier platform in the B2B2C market, expanding sales to employers, health plans, and strategic partners, while continuously enhancing our technology, product offering, and AI partners.

Speaker Change: Over the past year value of health.

Speaker Change: Undergone transformational shifts.

Evolving into a leading healthcare technology company operating on the fast like more than <unk>.

Speaker Change: And strategic partners, while continuously enhancing our technology for that.

Speaker Change: This evolution has solidified <unk> position as a premier platform in the <unk> market expanding sales to employers health plans and strategic partners, while continuously enhancing our technology.

Speaker Change: Hopefully I can I follow up.

The acquisition Im assuming its integration of twin <unk> most significant today.

Speaker Change: All leadership in the industry I think one of the most comprehensive clinically integrated digital health platforms now.

Speaker Change: Can I follow up.

Erez Raphael: The acquisition and the seamless integration of Twill, Dario's most significant today, has strengthened our leadership in the industry, creating one of the most comprehensive clinically integrated digital health platforms. Now supporting five chronic conditions under a single, unified plan, we are uniquely positioned to meet the growing demand for consumer-centric whole-person care in an increasingly value-driven healthcare environment.

Speaker Change: The acquisition of the seamless integration of twin value most significant today.

Speaker Change: Now supporting five Ronny conditions under a single unified brand.

Speaker Change: Positioned to meet the growing demand for consumer centric question Ken.

Speaker Change: Leadership in the industry I think one of the most comprehensive clinically integrated digital health platforms now.

Speaker Change: And increasingly valuable and healthy environment.

Speaker Change: Now supporting five Ronny conditions under a single unified brand.

Speaker Change: All the market is evolving and why <unk> is well positioned the health care industry is experiencing a major shift.

Speaker Change: Positioned to meet the growing demand for consumer centric personal care.

Speaker Change: Two key trends are driving our growth.

Speaker Change: And increasingly valued live and healthy environment.

Speaker Change: The move towards the full person digital health and vendor consolidation.

Erez Raphael: How the market is evolving and why Dario is well positioned. The healthcare industry is experiencing a major shift. These two key trends are driving our growth. First, the move toward whole person, digital health, and vendor consolidation. Employers and health plans are demanding fewer, more integrated solutions that address multiple chronic conditions in a single platform. Point solutions are no longer sustainable.

Speaker Change: All the market is evolving and why <unk> is well positioned the health care industry is experiencing a major shift.

Speaker Change: Employers and health plans are demanding fuel more integrated solutions that addresses multiple chronic conditions in a single platform.

Speaker Change: Two key trends driving our growth.

Speaker Change: The move towards the whole person digital health and vendor consolidation.

Speaker Change: So much so no longer sustainable.

Speaker Change: Bias once platform that delivers multi condition.

Speaker Change: Employers and health plans are demanding fuel more integrated solutions.

Speaker Change: Moving on ROI and seamless integration with the existing systems.

Speaker Change: Multiple chronic conditions in a single platform.

Speaker Change: Positions ahead of this shift.

Speaker Change: Point solution, so no longer sustainable.

Speaker Change: The total acquisition has created one of the most comprehensive product portfolio in the industry, enabling us to deliver a multi condition solution of course metabolic behavior.

Erez Raphael: BIOS is one platform that delivers multi-conditioned care, proven ROI, and seamless integration with the existing Why are its positions ahead of this shift? The Twill Acquisition has created one of the most comprehensive product portfolios in the industry, enabling us to deliver a multi-conditioned solution across metabolic, behavioral, and musculoskeletal health. Our AI-powered platform now supports five chronic conditions, making Dario a leader in whole person care. One of the growing behavioral health and cardio-metabolic offerings, including partnerships with virtual providers, organizations like Mediobest and RULA, which Steven will cover later, allows us to serve a broader population while delivering scalable, cost-effective care solutions.

Speaker Change: Bias once platform that delivers multi condition.

Speaker Change: Moving on ROI and seamless integration with the existing systems.

Speaker Change: And muscular skeletal health.

Speaker Change: Positioned ahead of this shift.

Speaker Change: Alright, I pause platform now supports five chronic conditions, making value a leader in whole person care.

Speaker Change: The twin acquisition has created one of the most comprehensive product portfolio in the industry, enabling us to deliver a multi condition solution of course metabolic behavioral and muscular skeletal health.

Speaker Change: The growing behavioral health and covenant diabolical filling including partnerships with Vishal provides us organizations like maybe August and Wala, which Stephen will cover later.

Speaker Change: Ali I pause platform now supports five chronic conditions, making value a leader in whole person care.

Speaker Change: Allows us to serve a broader population, while delivering scalable cost effective solutions.

Speaker Change: One of the growing behavioral health and covenant public offering.

Speaker Change: Including partnerships with virtual providers organizations like maybe August and Orla, which Stephen will cover later allows us to serve a broader population, while delivering scalable cost effective solutions.

Speaker Change: The second major shift is the rise of <unk> therapies, and the need for a long term view and lifestyle support the rapid adoption of GOP, one medications has transformed the health care landscape.

Erez Raphael: The second major shift is the rise of GLP-1 therapies and the need for a long-term behavioral and lifestyle change. The rapid adoption of GLP-1 medications has transformed the healthcare landscape, and our clients recognize that the medication alone is not enough. Employers and health plans are prioritizing comprehensive solutions that ensure sustainable, weightless metabolic health and performance. Dario has emerged as a leader in the GLP-1 companion space, supporting members before, during, and after treatment. Our integrated behavioral, metabolic, and digital coaching approach is a key differentiator helping employers and payers manage the significant costs associated with the GLP-1 treatments which ensure long-term health improvement.

Speaker Change: The second major shifts is the rise of geography, one therapies and the need for a long term view has a lot in.

Speaker Change: Clients recognize that the medication alone is not enough.

Speaker Change: Employers and health plans are prioritizing comprehensive solutions that ensure sustainable weightless metabolic health and cost controls.

Speaker Change: And lifestyle support the rapid adoption of GOP, one medications has transformed the health care landscape.

Speaker Change: Value has emerged as a leader in the gym for one companion space supporting members before during and after treatment.

Speaker Change: Our clients recognize that the medication alone is not enough employers and health plans are prioritizing comprehensive solutions that ensure sustainable weightless metabolic health and consequently bell.

Speaker Change: Integrated <unk> metabolic and digital coaching approach is a key differentiator.

Speaker Change: <unk> has emerged as a leader in the Gen. One companion space supporting members before during and after treatment.

Think employers manage.

Speaker Change: Manage those significant cost associated with the <unk> treatments, which ensure long term health improvements.

Speaker Change: <unk> metabolic and digital coaching approach is a key differentiator.

Speaker Change: The demand is directly reflected in our commercial success.

Speaker Change: Inc employers.

Speaker Change: Our new client wins in 2024, well directly tied to <unk> solutions our <unk>.

Speaker Change: <unk> managed those significant cost associated with the Jetblue one treatments.

Speaker Change: The one companion model that is now including also prescription capabilities has been instrumental in securing them those contracts.

Speaker Change: Which ensure long term health improvements.

Erez Raphael: The demand is directly reflected in our commercial success. Ten of our new client wins in 2024 were directly tied to GFP-1 solutions. Our GFP-1 companion model that is now including also prescription capabilities has been instrumental in securing employers' contracts. These organizations seek comprehensive solutions that address obesity and metabolic health while controlling costs.

Speaker Change: The demand is directly reflected in our commercial success.

Speaker Change: 10 of our new client wins in 2024 were directly tied to GFP1 solutions. Our GFP1 companion model that is now including also prescription capabilities has been instrumental in securing

Speaker Change: Monetization six comprehensive solutions that address this obesity and metabolic health while controlling costs.

Speaker Change: Yeah.

Speaker Change: Is a major driver of our competitive advantage.

Speaker Change: The evolution of rising health care and value is uniquely positioned to lead this transformation.

Speaker Change: as organizations seek comprehensive solutions that addresses obesity and

Speaker Change: Our approach called the acute meaning AI the third power literally just sufficient intelligent in three key ways.

Erez Raphael: AI is a major driver of our competitive advantage. AI is revolutionizing healthcare and Dario is uniquely positioned to lead this transformation.

Speaker Change: AI is a major driver of our competitive advantage. AI is revolutionizing healthcare and Dario is uniquely positioned to lead this transformation. Our approach to call the AI cubed, meaning AI, the third power, level is just sufficient intelligence in tricky ways.

Speaker Change: The first is operational efficiency power automation scanned engagement enhancements member interactions and reduces operational costs.

Erez Raphael: Our approach, called AI cubed, meaning AI, the third power, leverages artificial intelligence in three key ways. The first is operational efficiency, layout, power, automation, scaled engagement, enhancement, member interactions, and reduces operational costs. Number two is member engagement. AI drive hyper-personalized, delivers precise, proactive, and data-driven interventions, improving users' outcomes and retention. and number three, customer value. AI-backed analytics provides employers, health plans, and pharma clients with predictive insights enabling smarter, cost-effective healthcare decisions. This 25 years of users data collected by Dario and the companies we acquired with 5 million patients record. and billions of data points.

Speaker Change: Number two is member engagement AI to drive hyper personalized deliver precise roster and data driven intervention, improving users' outcomes and retention.

Speaker Change: And number three customer value.

Speaker Change: Number two is member engagement, AI drive a hyper-personal, delivers precise, positive and data-driven interventions, improving user outcomes and retention.

Speaker Change: <unk> analytics provides employers health plans and pharma clients with predictive insights, enabling smarter cost effective health care decisions.

Speaker Change: This 25 years of users data collected by downloading the companies we acquired.

Speaker Change: Number three, customer value. AI-backed analytics provides employers' health plans and palma clients with predictive insights and enabling smarter, cost-effective health-kill decisions.

Speaker Change: 5 million patient Psych ward.

Speaker Change: And billions of data points.

<unk> strategy is a game changer.

Speaker Change: This 25 years of users data collected by Dario and companies were acquired with 5 million

Speaker Change: <unk> engagement operational efficiency and.

Speaker Change: An important clinical and financially.

Speaker Change: Outcomes.

Speaker Change: We also reported our today, our strong financial and business performance for 2024.

Speaker Change: and Bingance of Data Points. DarioIQ's strategy is game changer that drives engagement to relational efficiency and important clinical and financial outcomes.

Erez Raphael: Dario's IQ strategy is a game changer that drives engagement, operational efficiency. and improve clinical and financial outcomes.

Speaker Change: Our full year 2024 results highlight the success of our strategy. The total revenue reached in 2024 was $27 million.

Erez Raphael: We also reported today a strong financial and business performance for 2020. Our full year 2024 results highlight the success of our start. The total revenue reached in 2024 is $27 million, 32.9% increase from $20.4 million in 2024. Q4 revenue grew by more than 110% compared to Q4 2023, and 2.4% sequentially compared to Q3 2024, reflecting continuous business expansion. B2B2C, employers and health plans' recurring revenue grew by approximately 400% year-over-year, with 35% of that growth coming from organic expansion. For former gross profit for a full business increased from 51% to 72%. Gross margins for our B2B2C business was about 80% from the last three quarters, reinforcing our trajectory towards sustainable profitability.

Speaker Change: We also reposied out today a strong financial and business performance for 2024.

Speaker Change: 32, 9% increase from $20 4 million in 'twenty.

Speaker Change: A full year, 2024, as well as highlight the success of our strategy. The total revenue reached in 2024 is $27 million, 32.9% increased from 20.4 million in 2023.

Speaker Change: Core revenue grew by more than 110% compared to Q4 dollars 23.

Speaker Change: And two 4% sequentially compared to Q3 and 24.

Speaker Change: <unk> continued business expansion.

<unk> see employers and health plans recurring revenue grew by approximately 400% year over year with 35% of that growth coming from organic expansion.

Speaker Change: took all revenue grow by more than 110% compared to Q4 2023 and 2.4% sequentially compared to Q3 2024, reflecting continued business expansion.

Speaker Change: <unk> gross profit.

Paul: Paul business increased from 51% to 70%.

Speaker Change: B2B2C, employers and health plants that come and grow by approximately 400% year over year with 35% of death growth coming from organic expansion.

Paul: Gross margins for our <unk> business was about 80% for the last three quarters reinforcing our trajectory towards sustainable profitability.

Speaker Change: The former growth profit for a full business increased from 51% to 72%, Grossman's for our beat-a-beatest seed business was about 80% for the last three quarters, reinforcing our objective, retrieved, sustainable, and positability.

Paul: Have you stopped pro forma operating expenses by 35% from Q1 2020 for Q4, 2024 and anticipate a further 20% reduction in our operating expenses by Q4 2025.

Erez Raphael: reduce our performer operating expenses by 35% from Q1 2024 to Q4 2024 and anticipate a further 20% reduction in our operating expenses by Q4 2024.

Paul: Keeping our contract for cash flow breakeven by the end of 2025.

Speaker Change: Well, it used out the formal operating expenses by 30% from Q1, 2020, Q4, 2020, Q4, and then anticipate the further 20% production in our operating expenses by Q4, 2025.

The successful $25 $6 million capital raised in January 2025, combined with our pro forma cash balance of $34 5 million as of December 31, 2024 provides us with a strong financial position to continue executing on our strategy.

Erez Raphael: Keeping our contract for Keshe Law for Refugees by the end of 2020.

Speaker Change: Pipping that contract for personal recovery by the end of 2025.

Erez Raphael: The successful $25.6 million capital raise in January 2025, combined with our performance cash balance of $34.5 million as of December 31st, 2024, provides us with the strong financial position to continue executing on our side.

Speaker Change: The successful 25.6 million dollar capital raise in January 2025 combined with a performer cash balance of 34.5 million, as of December 31, 2024, provides us with the strong financial position to continue executing on our strategy.

Paul: Looking ahead, our plan to grow in 2025.

Speaker Change: We look ahead, we plan to accelerate client growth and expand our business in 2020, Paul We won 36, new employers and health plans contrasts.

Speaker Change: Contracts, bringing the total client base to 83 organizations.

Erez Raphael: Looking at our plan to grow in 2025. As we look ahead, we plan to accelerate client growth and expand our business. In 2024, we won 36 new employers and health plans contracts, bringing the total client base to 83 organizations. Based on our pipeline and continued market demand, we are targeting a 50% net client growth in 2025, significantly expanding our footprint across employers, health plans, and pharmaceutical companies.

Speaker Change: Looking at our plan to grow in 2025, as we look ahead with them to accelerate to climb growth and expand our business.

Speaker Change: On our pipeline and continued market demand, we are targeting a 50% net client growth in 2025.

Speaker Change: In 2024, we won 36 new employers and health friends contracts bringing the total drive-based to 83 organizations.

Speaker Change: Significantly expanding our footprint cost employers health plans and pharmaceutical partnerships.

Speaker Change: With the final financial profile and market, leading AI powered platform and a clear strategy for expansion, we are well positioned to drive sustainable long term growth in the next few years.

Speaker Change: Based on our pipeline and continued market demand, we are targeting a 50% net-climbed growth in 2025, significantly expanding our footprint across employers' softness and from a typical partnership.

Erez Raphael: With a fine financial profile, a market-leading AI-powered platform, and a clear strategy for expansion, we are well-positioned to drive sustainable long-term growth in the next few years.

Steve: With that I will turn over the call to Steve <unk>, who will walk us through the commercial execution and client growth in more detail.

Speaker Change: With a financial profile, a marketing AI file platform and a clear strategy for expansion, we are well positioned to drive sustainable long-term growth in the next few years.

Speaker Change: Thank you, Eric and good morning, everyone I'm thrilled to share our Q4 and full year 2024 results marketing one of the most transformational years in Daurio health history.

Steven Nelson: With that, I'll turn over the call to Steven Nelson, who will walk you through the commercial execution and client growth in a more detailed manner. Thank you, Erez. And good morning, everyone.

Speaker Change: With that, I'll turn over the call to Steven Nelson, who will walk you through the commercial execution and client growth in a more detailed.

Speaker Change: Over the past months, we have accelerated client growth expanded our partnerships enhance our product offering and strengthened our financial foundation.

Steven Nelson: Thank you, Erez. And good morning, everyone. I am thrilled to share our Q4 in full year 2024 results, marking one of the most transformational years in DarioHealth's history.

Steven Nelson: I am thrilled to share our Q4 and full year 2024 results, marking one of the most transformational years in DarioHealth's Over the past months, we have accelerated client growth, expanded our partnerships, enhanced our product offering, and strengthened our financial foundation. continue to execute our vision of delivering a fully integrated AI-powered digital health platform. And we're seeing the impact of this strategy in both our commercial momentum and our financial performance.

Speaker Change: We've continued to execute our vision of delivering a fully integrated AI powered digital health platform and we're seeing the impact of the strategy in both our commercial momentum and our financial performance.

Steven Nelson: Over the past months we have accelerated client growth, expanded our partnerships, enhanced our product offering, and strengthened our financial foundation.

Speaker Change: As we enter 2025, we are well positioned for continued success and I am looking forward to walking you through the key highlights from our past year and the opportunities ahead.

Steven Nelson: We've continued to execute our vision of delivering a fully integrated AI-powered digital health platform, and we're seeing the impact of the strategy in both our commercial momentum and our financial performance.

Speaker Change: Our client growth and expansion in 2024 was a record breaking year with 36, new contracts signed bringing our total book of business to <unk> 83 clients across employers health plans and pharma.

Steven Nelson: As we enter 2025, we are well positioned for continued success, and I'm looking forward to walking you through the key highlights from our past year and the opportunities ahead.

Steven Nelson: As we enter 2025, we are well positioned for continued success and I'm looking forward to walking you through the key highlights from our past year and the opportunities ahead.

Speaker Change: Among these 10 wins were directly tied to <unk> solutions.

Steven Nelson: Our client growth and expansion in 2024 was a record-breaking year with 36 new contracts signed, bringing our total book of business to 83 clients across employers, health plans, and pharma. Among these, 10 wins were directly tied to GLP-1 solutions. reinforcing our growing demand for behavioral and lifestyle support for GLP-1 users. Our solution supports people at every stage of their GLP-1 treatment, from onboarding and staying engaged to offboarding successfully. This approach helps prevent weight regain and ensures long-term health improvement. By combining personalized digital health interventions with behavioral health coaching, we help clients optimize treatment effectiveness while reducing unnecessary cycle costs.

Steven Nelson: Our client Grossman Expansion in 2024 was a record breaking year with 36 new contract signed, bringing our total book of business to 83 clients across employers, health plans, and pharma.

Speaker Change: Forcing our growing demand for behavioral and lifestyle support for <unk> users.

Speaker Change: Our solution supports people at every stage of their <unk> treatment from Onboarding and staying engaged to Onboarding successfully.

Steven Nelson: Among these, ten wins were directly tied to GLP-1 solutions, reinforcing our growing demand for behavioral and lifestyle support for GLP-1 users.

Speaker Change: This approach helps prevent weight regain and ensures long term health improvements.

Steven Nelson: Our solution supports people at every stage of their GLP1 treatment from onboarding and staying engaged to offboarding successfully. This approach helps prevent regain and ensures long-term health improvements.

By combining personalized digital health interventions with behavioral health coaching we help clients optimize treatment effectiveness, while reducing unnecessary cycles.

Speaker Change: Ultimately driving better health outcomes and lowering long term costs.

Steven Nelson: By combining personalized digital health interventions with behavioral coaching, we help clients optimize treatment effectiveness while reducing unnecessary cycles.

Speaker Change: Additionally, our client renewal rate remained above 90% underscoring the strong value and impact of our platform.

Steven Nelson: Ultimately driving better health outcomes and lowering long-term costs. Additionally, our client renewal rate remained above 90%, underscoring the strong value and impact of our platform. This high retention rate reflects the effectiveness of our SAS-like model in delivering measurable ROI, driving sustained engagement, and ensuring long-term revenue predictability. These key factors position Dario for scalable, profitable growth in the evolving digital health landscape.

Speaker Change: This high retention rate reflects the effectiveness of our SaaS like model and delivering measurable ROI driving sustained engagement and ensuring long term revenue predictability.

Ultimately driving better health outcomes and lowering long-term costs.

Steven Nelson: Additionally, our client renewal rate remained above 90%, underscoring the strong value and impact of our platform. This high retention rate reflects the effectiveness of our SaaS-like model in delivering measurable ROI, driving sustained engagement, and ensuring long-term revenue predictability.

Speaker Change: These key factors position daurio for scalable profitable growth in the evolving digital health landscape.

Speaker Change: 2025 is already showing strong momentum with nine new client wins in just the first two months through both direct deals and strategic partnerships. This rapid start underscores our confidence in sustained accelerating revenue growth.

Steven Nelson: These key factors positioned Dario for scalable, profitable growth in the evolving digital health landscape.

Steven Nelson: 2025 is already showing strong momentum with nine new client wins in just the first two months through both direct deals and strategic partnership. This rapid start underscores our confidence in sustained, accelerating revenue growth.

Steven Nelson: 2025 is already showing strong momentum with nine new client wins in just the first two months through both direct deals and strategic partnerships. This rapid start underscores our confidence is sustained, accelerating revenue growth.

Speaker Change: Now, let's discuss our business channel updates starting with the employer segment.

Employer channel remains a key growth engine for Daurio as mid size and large employers increasingly consolidated digital health vendors in favor of integrated multi condition platforms that drive better outcomes and cost savings or <unk> companion solution has been a major entry point.

Steven Nelson: Now let's discuss our Business Channel Updates, starting with the Employer Segment. The Employer Channel remains a key growth engine for Dario as midsize and large employers increasingly consolidate digital health vendors in favor of integrated, multi-conditioned platforms that drive better outcomes and cost savings. Our GLP-1 companion solution has been a major entry point, as employers rank GLP-1 medications as their number one healthcare expense. Dario's comprehensive approach supports the full consumer journey, onboarding, active engagement during treatment, and structured off-boarding, ensuring sustained clinical outcomes while reducing unnecessary treatment cycles. Our new product packaging is already paying off, helping us win more deals and tailor solutions to different employers.

Speaker Change: Now let's discuss our business channel updates starting with the employer segment.

Speaker Change: EmployerChannel remains a key growth engine for Dario as midsize and large employers increasingly consolidate digital health vendors in favor of integrated multi-condition platforms that drive better health comes and cost savings.

Speaker Change: As employers ranked <unk> medications as their number one health care expense.

Speaker Change: <unk> comprehensive approach supports the full consumer journey onboarding active engagement during treatment and structured off boarding ensuring sustained clinical outcomes, while reducing unnecessary treatment cycles or new product packaging is already paying off helping us win more deals and tailor solutions.

Speaker Change: Our GLP-1 companion solution has been a major entry point as employers rank GLP-1 medications as their number one healthcare expense.

Speaker Change: Dario's comprehensive approach supports the full consumer journey, onboarding, active engagement during treatment, and structured off-boarding, ensuring sustained clinical outcomes while reducing unnecessary treatment cycles. Our new product packaging is already paying off, helping us win more deals and tailor solutions to different employers' needs.

Speaker Change: Two different employers' needs.

Speaker Change: Employers want solutions that improve health and save money.

Speaker Change: Mario makes this easy by tying our pricing to real results and simplifying how they pay.

Speaker Change: Employers demand ROI, driven digital health solutions, and <unk> is delivering by integrating clinical outcomes based payment models and seamless claims based billing, making adoption even easier.

Steven Nelson: Employers want solutions that improve health and save money. Dario makes this easy by tying our pricing to real results and simplifying how they pay. Employers demand ROI-driven digital health solutions, and Dario is delivering by integrating clinical outcomes-based payment models and seamless claims-based billing, making adoption even easier.

Speaker Change: Employers want solutions that improve health and save money. Dario makes this easy by tying our pricing to real results and simplifying how they pay. Employers demand ROI-driven digital health solutions, and Dario's delivering by integrating clinical outcomes-based payment models and seamless claims-based billing making adoption even easier.

Our strategy for employers in 2025 is direct and focused.

Speaker Change: We will expand employer adoption by leading with cardio metabolic and GOP one solutions addressing both the cost and long term health management challenges employers face.

Steven Nelson: Our strategy for employers in 2025 is direct and focused. We will expand employer adoption by leading with cardiometabolic and GLP-1 solutions, addressing both the cost and long-term health management challenges employers face. We will scale behavioral health services by integrating one of the largest virtual therapy networks in the US, ensuring employers can provide comprehensive support to their employees.

Our Strategy for Employers in 2025 is Direct and Focused.

Speaker Change: We will scale behavioral health services by integrating one of the largest virtual therapy networks in the U S. Ensuring employers can provide comprehensive support to their employees.

Speaker Change: The day, we announced our new strategic collaboration with ruler a leader in high quality behavioral Health services. This partnership gives Dario members direct access to rule as extensive network of over 15000 providers covering 120 million commercial lives.

Speaker Change: We will scale behavioral health services by integrating one of the largest virtual therapy networks in the US, ensuring employers can provide comprehensive support to their employees.

Steven Nelson: Friday, we announced our new strategic collaboration with RULA, a leader in high quality behavioral health services. This partnership gives Dario members direct access to ROLA's extensive network of over 15,000 providers. covering 120 million commercial lives. By combining RULA's provider network with our AI-driven digital behavioral health solutions, we are making it easier than ever for employers to offer seamless, high-quality mental health care. This is a major step forward in expanding Dario's behavioral health solutions and accelerating adoption across the employer market. We are simplifying how employers adopt Dario solutions by using claims data for smarter employee targeting, seamless billing, and clear proof of impact.

Speaker Change: Friday, we announce our new strategic collaboration with RULA, a leader in high quality behavioral health services. This partnership gives Dario members direct access to RULA's extensive network of over 15,000 providers, covering 120 million commercial lives.

Speaker Change: By combining rule as provider network with our AI driven digital behavioral health solutions, we are making it easier than ever for employers to offer seamless high quality mental health care.

Speaker Change: This is a major step forward in expanding Dario is behavioral health solutions and accelerating adoption across the employer market.

Speaker Change: By combining RULAs provider network with our AI-driven digital behavioral health solutions, we are making it easier than ever for employers to offer seamless, high-quality mental health care.

Speaker Change: We are simplifying how employers adopt daria solutions by using claims data for smarter employees targeting seamless billing and clear proof of impact and we will drive sales execution through a refined go to market approach focused on targeting employer segments accelerating pipeline conversion and deepening existing.

Speaker Change: This is a major step forward in expanding Dario's behavioral health solutions and accelerating adoption across the employer market.

Speaker Change: We are simplifying how employers adopt Dario solutions by using claims data for smarter employees targeting seamless billing and clear proof of impact.

Speaker Change: <unk> relationships.

Speaker Change: The opportunity in the employer market is massive with a growing client base and expanding product portfolio and our commercial model built for scalability Dario is positioned to lead the next phase of digital health adoption driving sustainable revenue growth and long term employer partnerships in 2025 and beyond.

Steven Nelson: And we will drive sales execution through a refined go-to-market approach focused on targeting employer segments, accelerating pipeline conversion, and deepening existing client relationships.

Speaker Change: and we will drive sales executions through a refined go-to-market approach focused on targeting employer segments, accelerating pipeline conversion and deepening existing client relationships.

Steven Nelson: The opportunity in the employer market is massive, with a growing client base and expanding product portfolio and a commercial model built for scalability, Dario is positioned to lead the next phase of digital health adoption, driving sustainable revenue growth and long term employer partnerships in 2025.

Speaker Change: Shifting now to our health plan strategy to help fund channel is a critical growth driver for Daurio as payers increasingly seek scalable multi condition digital health solutions that drive better outcomes reduce costs and improve member engagement.

Steven Nelson: Shifting now to our health plan strategy. The health plan channel is a critical growth driver for Dario as payers increasingly seek scalable, multi-condition digital health solutions that drive better outcomes, reduce costs, and improve member engagement. We are approaching health plans in two key ways. First, by supporting their existing lines of business with multi-conditioned digital health bundles, allowing payers to seamlessly integrate Dario's solutions into their care models and provide comprehensive chronic disease management to their members. That's the force, engagement and clinical outcome. Our dual approach is gaining strong traction with active engagement from all our partners.

Speaker Change: We are approaching health plans in two key ways.

Speaker Change: First by supporting our existing lines of business with multi condition digital health bundles, allowing payers to seamlessly integrate <unk> solutions into their care models and provide comprehensive chronic disease management to their members.

Speaker Change: First, by supporting their existing lines of business with multi-conditioned digital health bundles, allowing payers to seamlessly integrate Dario solutions into their care models and provide comprehensive chronic disease management to their members.

Speaker Change: Second by leveraging our platform to solve payer specific challenges within their infrastructure and product offerings, providing a platform as a service model that enhances operational efficiencies engagement and clinical outcomes are.

Speaker Change: Our dual approach is gaining strong traction with active engagement from all of our partners.

Speaker Change: One major payer has already committed to transitioning to daria mined this year, which will enhance our revenue for the second half of 2025. Additionally, we expect to add a full suite offering with one of the largest insurance companies in the U S market by mid year, which will also contribute to revenue this year.

Speaker Change: Our dual approach is gaining strong traction with active engagement from all our partners.

Steven Nelson: One major payer has already committed to transitioning to DarioMind this year, which will enhance our revenue for the second half of 2025. Additionally, we expect to add a full suite offering with one of the largest insurance companies in the U.S. market by mid-year, which will also contribute to revenue this year. Medicare Advantage and Medicaid are rapidly shifting to digital first. especially in areas where Dario already excelled. Cardiometabolic and Behavioral Health. This creates a major growth opportunity for Dario as we strengthen partnerships with national payers and expand our presence in government-sponsored programs. By integrating our solutions more deeply into existing health plans, we are aligning with commercial, Medicare Advantage, and Medicaid's increased focus on managing chronic conditions through digital health.

Speaker Change: One major payer has already committed to transitioning to Dario Mind this year, which will enhance our revenue for the second half of 2025 Additionally, we expect to add a full suite offering with one of the largest insurance companies in the US market by mid year, which will also contribute to revenue this year.

Speaker Change: Medicare advantage and Medicaid are rapidly shifting to digital first here, especially in areas, where daurio already excels cardio metabolic and behavioral health.

Speaker Change: This creates a major growth opportunity for <unk> as we strengthened partnerships with national payers and expand our presence in government sponsored programs.

Speaker Change: Medicare Advantage and Medicaid are rapidly shifting to digital first care, especially in areas where Dario already excels, cardiometabolic, and behavioral health.

Speaker Change: By integrating our solutions more deeply into existing health plans, we are aligning with commercial Medicare advantage and Medicaid is increased focus on managing chronic conditions through digital health expanding behavioral health access is a critical part of this transformation and our recently announced collaboration with roller strengthens our ability to.

Speaker Change: This creates a major growth opportunity for Dario as we strengthen partnerships with national payers and expand our presence in government-sponsored programs.

Speaker Change: By integrating our solutions more deeply into existing health plans, we are aligning with commercial, Medicare Advantage, and Medicaid's increased focus on managing chronic conditions to digital health.

Speaker Change: Support payers by combining <unk> AI driven engagement with one of the most extensive behavioral health provider networks in the country.

Steven Nelson: Expanding behavioral health access is a critical part of this transformation, and our recently announced collaboration with ROLA strengthens our ability to support payers by combining Dario's AI-driven engagement with one of the most extensive behavioral health provider networks in the country. Because RULA is an in-network provider for most major health plans, this integration makes it even easier for payers to adopt Dario's behavioral health solutions, streamlining access to ensuring members get the care they need. Moving forward, we will continue embedding our multi-conditioned digital health solutions into payer products and benefits. We are rapidly scaling our platform as a service model, giving payers the AI-driven tools they need to solve key challenges, making Dario's technology even more essential to their business.

Speaker Change: Expanding behavioral health access is a critical part of this transformation and our recently announced collaboration with Rola strengthens our ability to support payers by combining Dario's AI-driven engagement with one of the most extensive behavioral health provider networks in the country.

Speaker Change: Because ruler is an in network provider for most major health plans. This integration makes it even easier for payers to adopt doritos behavioral health solutions streamlining access to ensuring members get the care they need.

Speaker Change: because Rola is an in-network provider for most major health plans. This integration makes it even easier for payers to adopt Dario's behavioral solutions, tree-lining access to ensuring members get the care they need.

Speaker Change: Moving forward, we will continue embedding our multi condition digital health solutions into payer products and benefits.

Speaker Change: We are rapidly scaling our platform as a service model, giving.

Speaker Change: Giving payers the AI driven tools, they need to solve key challenges, making Darius technology, even more essential to their business.

Speaker Change: Moving forward, we'll continue embedding our multi-conditioned digital health solutions into to pay your products and benefits.

Speaker Change: <unk> is at the forefront of digital health Revolution for payers setting new industry standards for innovation and impact with a strong foundation expanding partnerships and measurable impact we are set to drive deeper adoption and long term revenue growth.

Speaker Change: We are rapidly scaling our platform as a service model, giving payers the AI-driven tools they need to solve key challenges, making Dario's technology even more essential to their business.

Steven Nelson: Dara is at the forefront of digital health revolution for payers, setting new industry standards for innovation and impact.

Speaker Change: Dario is at the forefront of digital health revolution for payers, setting new industry standards for innovation and impact. With a strong foundation, expanding partnerships and measurable impact, we are set to drive deeper adoption and long-term revenue growth.

Speaker Change: Now, let's dive into another exciting area of growth, our pharma and medical devices segment.

Steven Nelson: With a strong foundation, expanding partnerships, and measurable impact, we are set to drive deeper adoption and long-term revenue growth.

Speaker Change: This channel continues to evolve into a high value reoccurring revenue stream for Daurio reinforcing our position as a trusted digital health partner for leading pharmaceutical companies as.

Steven Nelson: Now let's dive into another exciting area of growth, our pharma and medical devices. This channel continues to evolve into a high-value, reoccurring revenue stream for Dario, reinforcing our position as a trusted digital health partner for leading pharmaceutical companies. As pharma increasingly prioritizes digital engagement in patient-centered care, we are seeing two primary ways they are leveraging Dario's platform to drive impact. First, pharma companies are engaging with Dario through our Platform-as-a-Service model, which has been further enhanced through our partnership with MediOrbit. This allows pharma to integrate virtual care, prescribing capabilities, and remote patient monitoring into their own therapeutic programs, creating a more seamless and comprehensive approach to patient management.

Speaker Change: Now let's dive into another exciting area of Gross, our Pharma and Medical Devices segment.

Speaker Change: As pharma increasingly prioritizes digital engagement and patient centered care. We are seeing two primary ways. They are leveraging <unk> platform to drive impact.

Speaker Change: This channel continues to evolve into a high value reoccurring revenue stream for Dario, reinforcing our position as a trusted digital health partner for leading pharmaceutical companies.

Speaker Change: First pharma companies are engaging with daurio through our platform as a service model, which has been further enhanced through our partnership with many Orbis. This allows farm and integrate virtual care prescribing capabilities and remote patient monitoring into their own therapeutic programs, creating a more seamless and comprehensive approach.

Speaker Change: As Pharma increasingly prioritizes digital engagement in patient-centered care, we are seeing two primary ways they're leveraging Dario's platform to drive impact.

Speaker Change: First, pharma companies are engaging with Dario through our platform as a service model, which has been further enhanced through our partnership with MediOrbis.

Speaker Change: <unk> to patient management.

As pharma moves toward more direct models of patient support Daurio scalable digital infrastructure provides customized solutions that improve real world patient support streamlined access to care and enhanced long term adherence. This platform as a service model is gaining traction with several leading pharma company.

Speaker Change: This allows farm and integrate virtual care, prescribing capabilities, and remote patient monitoring into their own therapeutic programs, creating a more seamless and comprehensive approach to patient management. [inaudible]

Steven Nelson: As pharma moves toward more direct models of patient support, Dario's scalable digital infrastructure provides customized solutions that improve real-world patient support, streamlined access to care, and enhanced long-term adherence. This platform-as-a-service model is gaining traction, with several leading pharma companies already exploring how Dario's expanded capabilities can deliver end-to-end digital health solutions. further strengthening our position in this high value market. Our collaboration with Sanofi has already transitioned into a commercial reoccurring revenue model providing a blueprint for how pharma can leverage Dario's platform to create sustainable, digital-first patient support solutions. Five major pharma and medical device companies, including Sanofi, are already using this model.

Speaker Change: As Pharma moves toward more direct models of patient support, Dario's scalable digital infrastructure provides customized solutions that improve real-world patient support, streamlined access to care, and enhanced long-term adherence.

Speaker Change: As already exploring how <unk> expanded capabilities can deliver end to end digital health solutions further strengthening our position in this high value market.

Speaker Change: This platform as a service model is gaining traction with several leading pharma companies already exploring how Dario's expanded capabilities can deliver end-to-end digital health solutions further strengthening our position in this high-value market.

Speaker Change: Our collaboration with Sanofi has already transitioned into a commercial reoccurring revenue model, providing a blueprint for how pharma and leveraged oreos platform to create sustainable digital first patient support solutions.

Speaker Change: Our collaboration with Sinofi has already transitioned into a commercial, reoccurring revenue model, providing a blueprint for Alpharma, can leverage Dario's platform to create sustainable, digital first, patient support solutions.

Speaker Change: Five major pharma and medical device companies, including Sanofi are already using this model. This shows strong and growing demand for digital health tools that support their treatments.

Speaker Change: Second pharma and medical device companies are increasingly turning to Daria mind as a digital therapeutic solution to support patients before during and after treatment.

Speaker Change: Five major pharma and medical device companies, including Sonofi, are already using this model. This shows strong and growing demand for digital health tools that support their treatments.

Steven Nelson: This shows strong and growing demand for digital health tools that support their treatment. Second, pharma medical device companies are increasingly turning to DarioMind as a digital therapeutic solution to support patients before, during, and after. This approach ensures that patients receive the mental health and lifestyle interventions needed to improve adherence, enhance outcomes, and create a more holistic care experience. With our new partnership with RULA, we're further strengthening the behavioral health ecosystem available to patients, giving them access to a broad provider network alongside Dario's digital intervention. Since ROLA is in network with most major health plans, pharma partners can now integrate behavioral health support more seamlessly into patient engagement strategies, driving better adherence and long-term treatment success.

Speaker Change: This approach ensures that patients receive the mental health and lifestyle interventions needed to improve adherence enhance outcomes and create a more holistic care experience.

Speaker Change: Second, Farm and Medical Device companies are increasingly turning to Dario Mind as a digital therapeutic solution to support patients before, during and after treatment.

Speaker Change: With our new partnership with ruler, we're further strengthening the behavioral health ecosystem available to patients, giving them access to a broad provider network alongside Dario digital interventions.

Speaker Change: This approach ensures that patients receive the mental health and lifestyle interventions needed to improve adherence, enhance outcomes, and create a more holistic care experience.

Speaker Change: Since rollout is in network with most major health plans pharma partners can now integrate behavioral whole support more seamlessly into patient engagement strategies, driving better adherence and long term treatment success.

Speaker Change: With our new partnership with Rula, we're further strengthening the behavioral health ecosystem available to patients, giving them access to a broad provider network alongside Dario's digital interventions.

Speaker Change: Since RULA is in-network with most major health plans, FARMA partners can now integrate behavioral health support more seamlessly into patient engagement strategies, driving better adherence and long-term treatment success.

Speaker Change: With virtual care prescribing and digital therapeutics now part of our platform Dario is transforming how pharma and medical device companies connect with and support patients.

Speaker Change: As we close out 2024, it's clear that <unk> has entered a new phase of growth execution and market leadership.

Steven Nelson: With virtual care, prescribing, and digital therapeutics now part of our platform, Dario is transforming how pharma and medical device companies connect with and support patients.

Speaker Change: With virtual care prescribing and digital therapeutics now part of our platform, Dario is transforming how pharma and medical device companies connect with and support patients.

Speaker Change: We have expanded our reach strengthened our financial foundation and positioned ourselves at the forefront of digital health innovation.

Steven Nelson: As we close out 2024, it's clear that Dario has entered a new phase of growth, execution and market leadership. We have expanded our reach, strengthened our financial foundation, and positioned ourselves at the forefront of digital health innovation. The results speak for themselves. Our strategy is working and we are just getting started. The increasing demand for whole-person, multi-conditioned care, combined with our ability to drive meaningful health and financial outcomes, puts us in a strong position to accelerate growth in 2025 and beyond. Looking ahead, we remain focused on scaling our commercial success, deepening client relationships, and continuing to innovate with AI driven solutions that maximize engagement and efficiency.

Speaker Change: As we close out 2024, it's clear that Dario has entered a new phase of growth, execution and market leadership.

Speaker Change: The results speak for themselves our strategy is working and we are just getting started.

Speaker Change: The increasing demand for whole person multi condition care combined with our ability to drive meaningful health and financial outcomes puts us in a strong position to accelerate growth in 2025 and beyond.

Speaker Change: We have expanded our reach, strengthened our financial foundation, and positioned ourselves at the forefront of digital health innovation.

Speaker Change: The results speak to themselves. Our strategy is working and we are just getting started.

Speaker Change: Looking ahead, we remain focused on scaling our commercial success deepening client relationships and continuing to innovate with AI driven solutions that maximize engagement and efficiency.

Speaker Change: With strong revenue streams, expanding partnerships and a clear path to long term profitability.

Speaker Change: <unk> is ready to deliver sustained value for our customers members and shareholders.

Erez Raphael: With that I will turn it back to you Erez.

Erez Raphael: With strong revenue streams, expanding partnerships, and a clear path to long-term profitability, Dario is ready to deliver sustained value for our customers, members, and shareholders.

Speaker Change: Strong revenue streams, expanding partnerships and a clear path to long term profitability Dario.

Erez Raphael: Thank you Steven.

Erez Raphael: As we conclude today's discussion.

Speaker Change: <unk> is ready to deliver sustained value for our customers members and shareholders.

Erez Raphael: 24 was transformation on you called out in Ohio.

We are entering 2025 with strong momentum and a solid financial foundation and a clear strategic vision that sets us apart in the healthcare technology space.

Erez Raphael: With that, I will turn it back to you.

Erez Raphael: With that I will turn it back to you Erez.

Erez Raphael: Thank you, Steven. As we conclude today's discussion, it's clear that 2024 was a transformational year for DarioHealth. We are entering 2025 with strong momentum, a solid financial foundation, and a clear strategic vision that sets us apart in the healthcare technology. We have successfully executed our strategy. Spending our B2B2C business, integrating twin, deepening our employers and health friends relationships, and strengthening our position in the GLP-1 model. We have built a comprehensive AI-powered whole-person digital health platform that delivers real value to our clients by improving health outcomes and reducing costs. At the same time, we are trying our financial profile and business model, making Dario a more efficient, scalable, and sustainable company.

Erez Raphael: Thank you Steven.

Speaker Change: Now let me conclude today's discussion it's clear the 2024 was transformation on you called out in Ohio.

Erez Raphael: We have successfully executed our strategy.

Erez Raphael: Pending all <unk> business integrating twin dipping, our employer and health plan relationships and strengthening our position in the <unk> one market.

Speaker Change: Entering 2025 with strong momentum and a solid financial foundation, and a clear strategic vision that sets us apart in the healthcare technology space.

Speaker Change: We have successfully executed our strategy expanding our <unk> business.

Erez Raphael: We have a comprehensive AI followed the whole person digital health platform that delivers real value to our clients by improving health outcomes and reducing costs.

Speaker Change: <unk> twin dipping, our employer and health plan relationships and strengthening.

Speaker Change: <unk> one markets.

Erez Raphael: At the same time, we are saying.

Speaker Change: We have a comprehensive AI followed the whole person digital health platform that delivers real value to our clients by improving health outcomes and reducing costs.

Erez Raphael: Our financial goals and business model, making valeo and more efficient scalable and sustainable company.

Erez Raphael: Revenue growth combined with disciplined expense management has positioned us for long term profitability and our ability to drive recurring revenue.

Speaker Change: At the same time, we are saying.

Speaker Change: Our financial goals and business model, making valeo and more efficient scalable and sustainable company.

Erez Raphael: So China, including pharma provides vertical financial predictability and stability.

Erez Raphael: Revenue growth combined with disciplined expense management has positioned us for a long-term profitability and our ability to drive recurring revenue across all channels, including pharma, provides greater financial predictability and stability.

Speaker Change: <unk> growth combined with disciplined expense management has positioned us for long term profitability and our ability to drive recurring revenue.

Erez Raphael: Looking at our strategy for 2020 will focus on three key priorities.

Erez Raphael: Number one extended I think commercial growth.

Speaker Change: So China, including former provides vertical financial predictability and stability.

Erez Raphael: We aim to expand our employer and health plan adoption, depending existing partnerships and increased penetration.

Erez Raphael: Looking at our strategy for 2025, we'll focus on three key priorities. Number one, accelerating commercial growth. We aim to extend our employers' and health plans' adoption, deepen existing partnerships, and increase penetration in the payer and the farmer market. Our goal is to increase our total number of accounts by 50%, with GLP-1 solutions remaining a key driver, as employers and health plans recognize the need for cost management and long-term behavioral and lifestyle support beyond the medication.

Speaker Change: Looking at our strategy for 2020 will focus on three key priorities.

<unk> in the plan and the pharma markets.

Speaker Change: Number one extended I think commercial growth.

Erez Raphael: Our goal is to increase our total number of that caused by 50% will just be one solution for remaining a key driver.

Speaker Change: We aim to expand our employers and health plans to adoption.

Erez Raphael: As employers and health plans cycle denies the medical cost management, and long term behavioral and lifestyle support beyond the medication alone.

Speaker Change: <unk> been existing partnerships in and.

Speaker Change: Penetration in the Pan and the pharma market.

Speaker Change: Our goal is to increase our total number of that caused by 50% will just be one solution of remaining a key driver.

Erez Raphael: Second one is leaving the market shift toward personal digital health.

Speaker Change: Employers and health plans cycle behind the need for cost management, and wholesale and lifestyle support beyond the medication alone.

Erez Raphael: Market is moving away from augmented point solutions, both integrated multi condition platforms to deliver better outcomes and cost efficiencies.

Erez Raphael: Second one is leading the market shift to whole person digital health. The market is moving away from automated point solution. both integrated multi-conditioned platforms that deliver better outcomes and cost-efficient. This shift has only been reinforced by GFP1 adoption, which underscores the importance of holistic whole person care. Dario is uniquely positioned to capitalize on this transition with Iyar Fahd. multi-conditional.

Speaker Change: Second one is leaving the market shifts towards personal digital health <unk>.

Erez Raphael: This shift has only been reinforced by GOP, one adoption, which underscores the importance of holistic harperson cow.

Speaker Change: Market is moving away from point solutions, both integrated multi condition platforms to deliver better outcomes and cost efficiencies.

<unk> is uniquely positioned to capitalize on this transition where they all powered.

Speaker Change: This shift has only been reinforced by Jeff do you want adoption.

Erez Raphael: Multi condition approach.

Erez Raphael: Number three is driving operational efficiencies and profitability.

Speaker Change: Which underscores the importance of holistic whole person care.

Speaker Change: <unk> is uniquely positioned to capitalize on this transition with layoffs powered.

Erez Raphael: We will continue to optimize our cost structure and take opex down by another 20% by.

Speaker Change: Multi condition approach.

Erez Raphael: By Q4 this year.

Erez Raphael: Number three, driving operational efficiencies and profitability. We'll continue to optimize our cost structure and take OPEX down by another 20%. by Q4 of this year. scale our SAS-like model and remain on track for operational cash flow breakeven by the end of 2025. With continued operational discipline and AI-driven efficiencies, we believe we can drive long-term sustainable profitability. We have the right strategy, the right team, the right momentum to continue delivering affordable, scalable growth. and to use the hat.

Speaker Change: Number three driving operational efficiencies and profitability.

Erez Raphael: Hello, SaaS like model and remain on track for operational cash flow breakeven by the end of 2020 with.

Speaker Change: We will continue to optimize our cost structure and take opex down by another 20% by.

Erez Raphael: With continued operational discipline and AI driven efficiencies, we believe we can drive long term sustainable profitability.

Speaker Change: By Q4 this year.

Speaker Change: Hello, SaaS like model and remain on track for operational cash flow breakeven by the end of 2020.

Erez Raphael: We have the right strategy the right team the right momentum to continue delivering profitable scalable growth.

Speaker Change: With continued operational discipline and AI driven efficiencies, we believe we can drive long term sustainable profitability.

Erez Raphael: Is that.

Now looking at the moment.

Erez Raphael: Thank our employees partners and investors for.

Speaker Change: We have the right strategy the right team the right momentum to continue delivering profitable scalable go.

Erez Raphael: For your continued support.

Erez Raphael: Thirdly excited about what's ahead.

Erez Raphael: Look forward to sharing the progress throughout 2025.

Speaker Change: And they use that.

Erez Raphael: I want to take the moment to thank our employees, partners, and investors for your continued support. We're incredibly excited about what's ahead, and I look forward to sharing the progress throughout 2025. Thank you.

Speaker Change: Also at the moment.

Erez Raphael: Okay.

Speaker Change: Our employees partners and investors.

Erez Raphael: Okay.

Erez Raphael: Thank you, ladies and gentlemen, who will now begin the question and answer session should you have a question. Please press star followed by the one on your Touchtone phone, you'll hear a prompt that your hand hasn't been raised should you wish to decline from the polling process. Please press star followed by the truth.

Speaker Change: For your continued support.

Speaker Change: Thirdly excited about what's ahead.

Look forward to sharing the progress throughout 2025.

Speaker Change: Okay.

Speaker Change: Yeah.

Speaker Change: Yes.

Speaker Change: Thank you ladies and gentlemen.

Unknown Executive: Ladies and gentlemen, we will now begin the question-and-answer session. Should you have a question, please press star followed by the one on your touch-tone phone. You will hear a prompt that your hand has been raised.

Erez Raphael: If you are using a speaker phone please lift the handset before pressing any keys one moment. Please for your first question.

Speaker Change: The question and answer session should you have a question. Please press star followed by the one on your Touchtone phone, you'll hear a prompt that your hands. That's been raised should you wish to decline from the polling process. Please press star followed by the two.

Charles: Your first question comes from Charles <unk> with TD Cowen. Your line is now open.

Unknown Executive: Should you wish to decline from the polling process, please press star followed by the If you are using a speakerphone, please lift the handset before pressing any. One moment, please, for your first question.

Speaker Change: If you are using a speaker phone please lift the handset before pressing any keys one moment. Please for your first question.

Speaker Change: Thanks for taking the questions.

Charles: Or is it just wanted to ask sort of.

Speaker Change: On the on the GOP one.

Charles Rhyee: Your first question comes from Charles Rhyee with TD Cowan. Your line is now open. Thanks for taking the questions. Erez, I just wanted to ask sort of on the GLP-1 support programs, you talked about obviously able to help sort of onboard as well as, you know, support through treatment and then sort of the offboarding part. Curious, you know, to the extent that, you know, what number of patients or members have you seen successfully offboard, you know, given sort of this idea that, you know, for most people this could end up being sort of a lifetime treatment.

Charles: Your first question comes from Charles <unk> with TD Cowen. Your line is now open.

Charles: Support programs.

Charles: You talked about obviously, you're able to help sort of onboard as well as support.

Charles: Thanks for taking the questions.

Charles: Or is it just wanted to ask sort of.

Charles: Support through treatment, and then sort of the off boarding part curious.

Charles: On the on the G. L P. One.

Charles: To the extent that what number of.

Charles: Support programs.

Charles: You talked about obviously, you're able to help sort of onboard as well as.

Speaker Change: Ah patients or members have you seen successfully off-board.

Charles: Given sort of this idea that for most people this could end up being sort of a lifetime treatment.

Charles: Support through treatment and then sort of the operating part curious.

Charles: To the extent that what number of.

Speaker Change: And perhaps what.

Speaker Change: What percentage of existing customers have elected to add the <unk> support solution.

Charles: Patients or members have you seen successfully off board.

Charles: Given sort of this idea that for most people this could end up being sort of a lifetime treatment.

Charles: Yeah. Thanks, Charles for the question so.

Charles Rhyee: And perhaps, you know, what percentage of existing customers have elected to add the GLP-1 support solution?

Charles: And perhaps you know what.

Speaker Change: Last year, we won.

Charles: What percentage of existing customers have elected to add the GOP one support solution.

Speaker Change: And accounts that have.

Speaker Change: That have the.

Speaker Change: The <unk> solution.

Speaker Change: But food the B to C. We had.

Charles: Yeah. Thanks, Charles for the question so.

Erez Raphael: Thanks Charles for the questions. Last year we won like 10 accounts that have the GLP-1 solution. But through the B2C, we had a few hundreds of users that already used it. So with the B2C users that were launched even before, we have seen a few hundreds that we already have some data about them. And actually, we did a specific study that will be eventually presented on the ADA that will provide the exact numbers. And that's something that we're going to publish in June of this year. So we have already some results on the off-boarding. More results we have on the on-boarding and our ability to help users go through the on-boarding of the process with the side effects and so on, and retain on the drug.

A few hundreds of.

Charles: Last year, we won.

Charles: And accounts that have.

Speaker Change: Users the ability to use it.

Speaker Change: So was the BTC users that really launched even before we have seen a few hundreds that we already have some data modem and actually we are we did a specific.

Charles: <unk>.

Charles: The DLP one solution.

Charles: But through the B to C. We had.

Charles: A few hundreds of.

Charles: Users the ability to use it.

Speaker Change: Specific.

Charles: So as the BDC use as well.

Speaker Change: Study that will be eventually presented on the Ada that will provide the exact numbers and that's something that we're going to publish in June of this year. So we have already.

Charles: When we launched even before we have seen a few hundreds that we already have some data modem and actually we are we did a specific.

Charles: Study that will be eventually presented on the Ada that will provide the exact numbers and that's something that we're going to publish in June of this year. So we have already.

Speaker Change: Some results on the on the overloading more results. We have won the onboarding and our ability to help users go through there.

Speaker Change: The onboarding of the process was the side effects and so on and the pain on the on the drug and also we have the capability to predict those that we'll be able to growth with the on boarding and get.

Charles: Some results on the on the Onboarding more results, we have won the onboarding and our ability to help users go through there.

Speaker Change: The effect based on data that we collected over time. So we have some data and that data will be published on a on a very organized study on June of this year.

Charles: The onboarding of the process was the side effects and so on and the pain on the on the drug.

Erez Raphael: And also, we have the capability to predict those that will be able to go through the on-boarding and get the effect based on data that we collected over time. So we have some data, and that data will be published on a very organized study in June of this year.

Charles: So we have the capability to predict those that we'll be able to growth would be onboarding and get there.

Speaker Change: And.

Speaker Change: I know youre, not giving 'twenty guidance, but any way to kind of give us some rough sense on what what to expect maybe broad strokes for your expectations for growth. This year end and maybe in that context.

Charles: The effect based on data that we collected over time. So we have some data and that data will be published on a on a very organized study in June of this year.

Erez Raphael: And I know you're not giving 25 guidance, but any way to kind of give us some rough sense on what to expect, maybe broad strokes for your expectations for growth this year? And maybe in that context, you know, what, how big of a percentage do you think GLP-1, the GLP-1 program will be as a percent of total revenue? Yeah, so last week, as we mentioned on the call, we were like, we were like winning 36 accounts. This year, we are targeting to go by more than 50 accounts. And that's obviously something that will impact more 2026 when we're looking into account because in 70% of the cases, the wins are going to generate the revenue the year after.

Charles: And.

Speaker Change: I know, you're not giving <unk> guidance, but.

Speaker Change: What how big of a percentage do you think GOP won the GOP one program will be as a as a percent of as a percent of total revenue.

Speaker Change: Any way to kind of give us some rough sense on what what to expect maybe broad strokes for your expectations for growth this year and maybe in that context.

Speaker Change: Yes, so last week as we mentioned on the call we really like.

Speaker Change: We will like winning 36 accounts. This year, we are targeting for goal by more than 50 accounts and Thats, obviously, something thats going to impact more 2026, when we're looking into account because 70% of the cases, the winds are going to generate the revenue and the year after.

Speaker Change: What how big of a percentage do you think GOP. One did you have one program will be as a as a percent of <unk> as a percent of total revenue.

Speaker Change: Yes, so last week as we mentioned on the call we were like.

Speaker Change: We were like winning 36 accounts. This year, we are targeting the goal by more than 50 accounts and that's obviously something thats going to impact more 2026, when we're looking into account because in 70% of the cases the wins are going to generate the revenue in the year after.

Speaker Change: We think that the.

Speaker Change: A third of what we are signing last year was related to GMP, one with things that the <unk> alone is going to at least double this year in terms of the number of accounts and how we are there and how we are.

Steven Nelson: We think that a third of what we were signing last year was related to GLP-1. We think that the GLP-1 alone is going to at least double this year in terms of the number of accounts and how we are penetrating it to the market. So we think that this is something that will have a big part of our revenues. Steven, if you want to add something. Yeah, I'll add, I think in the GLP-1 space, one of the things that we announced in January, I believe, actually, was our prescribing partner in MediOrbis. And that allows the employer, if they want to, if they want to, to prescribe accordingly as a part of their benefit design in general, or add controls, etc.

We think that the.

Speaker Change: A third of what we were signing the last deal was related to the G&P one with things that the <unk> alone is going to at least double this year in terms of the number of accounts and how we are there and how we are there.

Speaker Change: And penetrating into the market. So we think that this this is something that would have.

Speaker Change: We will have a big big part of our revenues.

Steven Nelson: Stephen if you want to add something.

Speaker Change: Yes.

Speaker Change: Penetrating into the market. So we think that this is something that we would have.

Speaker Change: I think in the <unk> space one of the things that we announced in January I believe actually was our our prescribing partner in many orbis and that allows the employer if they want to if they want to to prescribe accordingly, as a part of their benefit design.

Speaker Change: We have a big big part of our revenues.

Stephen: Stephen if you want to add something.

Steven Nelson: Yeah, I'll add I think in the <unk> space one of the things that we announced in January I believe actually was our our prescribing partner in many orbis and that allows the employer if they want to if they want to to prescribe accordingly, as a part of their benefit design.

In general or add controls et cetera. So I think it's one point to reference and again I could go further if you'd like me to but I won't unless you ask and then the second point that I think is probably as relevant is just because you're asking about G. L. P. One and I talked about it within that.

Steven Nelson: In general or add controls et cetera. So I think it's one point to reference and again I could go further if you'd like me to but I won't unless you ask and then the second point that I think is probably as relevant is just because you are asking about G. L. P. One and I talked about it within that.

Steven Nelson: So I think it's one point to reference. And again, I could go further if you'd like me to, but I won't, unless you ask. And then the second point that I think is probably as relevant is, just because you're asking about GLP-1, and I talked about it within today's discussion as well, which is, where is it headed? And clinically, there's a lot of information coming out about GLP-1, especially targeting end of year. And so as more clinical information and other information comes out on where it impacts and what it impacts, I think that's going to change the dynamic of it being only weight loss oriented today.

Speaker Change: Today's discussion as well, which is where is it headed and clinically theres a lot of information coming out about G. L. P. One.

Speaker Change: Especially targeting end of the year and so as more clinical information and other information comes out on where it impacts and what it impacts I think thats going to change the dynamic of it being only weight loss oriented today again, I'm not a doctor professional et cetera, like that but I think there's a lot coming down the path as well regarding clinical and clinical efficacy.

Steven Nelson: Those discussions as well, which is where is it headed and clinically theres a lot of information coming out about G. L. P. One.

Steven Nelson: Especially targeting end of year.

Steven Nelson: So as more clinical information and other information comes out on where it impacts and what it impacts I think thats going to change the dynamic of it being only weight loss oriented today again, I'm not a doctor professional et cetera, like that but I think there's a lot coming down the path as well regarding clinical and clinical FSP around other ways to GOP. One is also.

Speaker Change: Around other ways to <unk>. One is also use so weight loss is one thing and chronic conditions or another and there's a lot of data. This year that I think will be or at least just kind of round that out.

Steven Nelson: Again, I'm not a doctor, professional, etc. like that. But I think there's a lot coming down the path as well, regarding clinical and clinical efficacy around other ways that GLP-1 is also used. So weight loss is one thing, and chronic conditions are another.

Speaker Change: Maybe one more on <unk>, just real quickly how many employers are electing to have many overs prescribe it because my understanding is that if if you have a dedicated sort of prescribing network.

Steven Nelson: Use so weight loss is one thing and chronic conditions or another and there's a lot of data. This year that I think will be a release just to kind of round that out.

Steven Nelson: And there's a lot of data this year that I think will be released, just to kind of round that out.

Speaker Change: That kind of can impact sort of rebate calculations for on their pharmacy benefits side just curious.

Charles Rhyee: Maybe one more on GLP-1s just real quickly. How many employers are electing to have Mediobras prescribe it? Because my understanding is that if you have a dedicated sort of prescribing network that kind of can impact sort of rebate calculations for on their pharmacy benefit side. Just curious. It was a key part of our last year we evaluated some of our business wins and losses. We evaluate those as well. We needed that capability. We pinpointed that as a capability need that we had to have in our product. Again, as we kind of discussed today, very focused effort on execution, what we exactly need to bring to the market and round out.

Steven Nelson: Maybe one more on <unk>, just real quickly how many employers are electing to have many overs prescribe it because my understanding is that if if you have a dedicated sort of prescribing network.

Speaker Change: So absolutely real.

Speaker Change: Real easy right now no. We just launched it in January so we're taking it out and discussing it with all of them. It was a key part of our last year, we evaluated some of our business wins and losses, because we evaluate those as well we needed that capability. We pinpointed that has the capability need that we had to have in our product again as we kind of discussed today.

Steven Nelson: That kind of can impact sort of rebate calculations for on their pharmacy benefits side just curious.

Steven Nelson: So absolutely real.

Steven Nelson: Real easy right now no. We just launched it in January so we're taking it out and discussing it with all of them. It was a key part of our last year, we evaluated some of our business wins and losses, because we evaluate those as well we needed that capability. We pinpointed that has the capability need that we had to have in our product again as we kind of discussed today very.

Speaker Change: A focused effort on execution, what we exactly need to bring to the market and round out our G. L. P. One offering programmatically speaking in our cardio metabolic suite with strong already but we need to do is just have that option. That's all we really needed was it capability. So time will tell on how many pick up the option and also time will tell where the product.

Steven Nelson: Focused effort on execution, what we exactly need to bring to the market and round out our G. L. P. One offering programmatically speaking in our cardio metabolic suite with strong already but we need to do is just have that option. That's all we really needed was it capability. So time will tell on how many pick up the option and also time will tell where the product.

Erez Raphael: Our GLP-1 offering programmatically speaking in our cardiometabolic suite was strong already. What we need to do is just have that option. That's all we really need was a capability. So time will tell on how many pick up the option. And also time will tell where the product then, as I mentioned earlier, goes in terms of clinical care. So we'll be prepared for the future as well.

Speaker Change: And as I mentioned earlier goes in terms of clinical care. So we'll be prepared for the future as well.

Speaker Change: Got it and maybe just a couple of questions on the health plan side.

Speaker Change: It sounds like on the health plan side, the big focus has been and behavioral health.

Steven Nelson: As I mentioned earlier goes in terms of clinical care, So we'll be prepared for the future as well.

Speaker Change: Maybe talk about sort of the opportunities to expand our.

Unknown Executive: Got it.

Speaker Change: Got it maybe just a couple of questions on the health plan side.

Charles Rhyee: And maybe just a couple of questions on the health plan side. You know, it sounds like on the health plan side, the big focus has been behavioral health. Maybe talk about sort of the opportunities to expand offerings through the health plan side, you know, such as weight loss or any other cardiometabolic conditions. And, you know, have any of those discussions been going on with existing health plan partners? Yes, so I did announce today we noted towards something of the future, which was that we, you know, were expecting to sign a large health plan in the back half of the year.

Speaker Change: Offerings through the health plan side, such as weight loss or in the other cardio metabolic conditions and.

Speaker Change: It sounds like on the health plan side, the big focus has been and behavioral health.

Speaker Change: Have any of those discussions been going on with existing health plan partners.

Speaker Change: Maybe talk about sort of the opportunities to expand.

Speaker Change: Yes, so I did announce them today, we noted towards something in the future which was that we.

Speaker Change: Offerings through the health plan side, such as weight loss or in the other cardio metabolic conditions.

Speaker Change: We're expecting to sign a large health plan in the back half of the year.

Have any of those discussions has been going on with existing health plan partners.

Speaker Change: I think that's pretty innovative actually whenever we come out with what we're doing with them and how they're doing it in the market.

Speaker Change: Yes, so I did announce today, we noted towards something in the future, which was that we were expecting to sign a large health plan in the back half of the year.

Speaker Change: It is full suite. So it is all products. It's also very encouraging get the size and scale of having a full suite offering that allows us to do something with them. So yes.

Steven Nelson: I think it's pretty innovative, actually, whenever we come out with what we're doing with them and how they're doing in the market. It is full suite, so it is all products. It's also very encouraging, get the size and scale of having a full suite offering allows us to do something with them. So yeah, I think there's some opportunities there. I think that we're trying to be focused on what is our product market fit for now. And our best product market fit for now is enabling what would be our self care members in behavioral health, the ability to get that therapist if they need it.

Speaker Change: I think that's pretty innovative actually whenever we come out with what we're doing with them and how they're doing it in the market. It is full suite. So it is all products.

Speaker Change: I think there's some opportunities there I think that we're trying to be focused on what is our product market fit for now.

Speaker Change: And our best product market fit for now is enabling what would be our self care members and behavioral health the ability to get the therapist, if they need it.

Speaker Change: So very encouraging given the size and scale of having a full suite offering allows us to do something with them. So.

Speaker Change: Yeah, I think there's some opportunities there I think that we're trying to be focused on what is our product market fit for now.

And doing that with the payers in mind since they have their own therapists networks or one that we partnered with but they do have a contract with today.

Speaker Change: And our best product market fit for now is enabling what would be our self care members and behavioral health the ability to get to a therapist if they need it.

Speaker Change: We can close the loop with members. So if you need to see a therapist you should see a therapist and now we can help you see a therapist and after you see the therapist. The luxury of this is we'll take you back and then we'll put you back into our content world.

Steven Nelson: And doing that with the payers in mind, since they have their own therapist networks or one that we partner with, that they do have a contract with today, we can close the loop with members. So if you need to see a therapist, you should see a therapist. And now we can help you see a therapist. And after you see the therapist, the luxury of this is, we'll take you back. And then we'll put you back into our content world and understand how you are, where you are in self-care again. So we closed the loop now in behavioral health.

Speaker Change: And doing that with the payers in mind since they have their own therapists networks or one that we partnered with but they do have a contract with today.

Speaker Change: Understand how you are where you are in self care again, so we closed the loop now in behavioral health. So we're with them today and behavioral health, we're trying to expand with all of our partners in their own behavioral strategies. It's why we're focused on that as our first priority, but no doubt our second priority is where and how we can expand in cardio metabolic and we will have an expansion of use cases.

Speaker Change: We can close the loop with members. So if you need to see a therapist you should see a therapist and now we can help you see a therapist and after you see the therapist. The luxury of this is we'll take you back and then we'll put you back into our content World and understand how you are where you are in self care again. So we closed the loop now in behavioral health. So we're with them today and behavioral health.

Steven Nelson: So we're with them today in behavioral health. We're trying to expand with all of our partners in their own behavioral health strategies. It's why we're focused on that as our first priority. But no doubt, our second priority is where and how we can expand in cardiometabolic.

Speaker Change: That this year.

Speaker Change: We're trying to expand with all of our partners in their own behavioral strategies. It's why we're focused on that as our first priority, but no doubt our second priority is where and how we can expand in cardio metabolic and we will have an expansion of use case of that this year.

Speaker Change: Okay, maybe last question here last quarter.

Ed: As Ed talked.

Ed: <unk> talked about expecting about 35% growth in the health plan revenue and health plan revenue and $25 is still is that still the right target to think of.

Steven Nelson: And we will have an expansion use case of that this year.

Unknown Executive: Okay, thanks.

Speaker Change: Okay, maybe last question here last quarter.

Charles Rhyee: Maybe last question here. Last quarter, you guys had talked about expecting about 35% growth in the health plan revenue, in health plan revenue in 2025. Is this still the right target to think of? I'd rather do it in 25. Erez, do we go? Maybe I'll take this one. We are not guiding for how 2025-2026 are going to look like. In general, the growth rate that you mentioned is something that we are targeting in all the channels. That's generally what we are expecting. One more correction that I want to make. So you talked about the previous question, you assumed that you see more behavioral health that we are selling to health plan.

Ed: Okay.

Ed: 25.

Speaker Change: Guys that are talked.

Speaker Change: <unk> talked about expecting about 35% growth in the health plan revenue and health plan revenue in 25 years is still is that still the right target to think of.

Ed: Erez do would go.

Ed: Yes.

Ed: And maybe I'll take this one.

Ed: Uh huh.

Ed: We are guiding for how 2025 2026, we're going to look like.

Speaker Change: Okay.

Speaker Change: 25.

Speaker Change: Erez do would go.

Ed: In general the growth rate that you mentioned is something that we are targeting in order to China.

Speaker Change: Yes.

Speaker Change: And maybe I'll take this one.

Speaker Change: Uh huh.

Ed: Generally what we are expecting well I'm more collections that don't want to make so you you talked about the previous question you assumed that you see more via the web.

Speaker Change: We are guiding for how 2025 point in 2006, so it's going to look like.

Speaker Change: In general the growth rate that you mentioned is something that we are targeting in order to China.

Ed: Now that we are sending to health plan I think that from a revenue perspective, and also from a win rate perspective.

Speaker Change: Yes.

Speaker Change: Generally what we are expecting well I'm more collections that don't want to make so you you talked about the previous question you assumed that you see more via the web.

Ed: I don't think that health is going to be greater than the cardio metabolic we need to remember that value built the cardio metabolic solution for many years and we have one of the most advanced other metabolic solution and will have built a very advanced behavioral health solution. Both of them are being sold in the market as a standalone Hello and also.

Speaker Change: <unk> that we are sending to health plan I think that from a revenue perspective, and also from a win rate perspective.

Erez Raphael: I think that from a revenue perspective and also from a win rate perspective, I don't think that behavioral health is going to be greater than the cardiometabolic. We need to remember that Dario built a cardiometabolic solution for many years, and we have one of the most advanced cardiometabolic solutions. And Twill have built a very advanced behavioral health solution. Both of them are being sold in the market as a standalone and also as a full suite. So I don't think that from a win perspective or revenue perspective, the behavioral health is going to be greater than the metabolic.

Speaker Change: I don't think the behavioral health is going to be greater than the cardio metabolic we need to remember that <unk> built the cardio metabolic solution for many years and we have one of the most advanced another metabolic solution and will have built a very advanced behavioral health solution. Both of them are being sold in the market as a standalone Hello and also.

Ed: Full suite, so I don't think that from a wind perspective or revenue perspective, the behavioral health is going to be greater than <unk>.

Ed: Metabolic I think that the <unk>.

Ed: Eventually when we're looking on the average revenue per user.

Ed: Quality is larger in terms of revenue.

The full suite, so I don't think that from a wind perspective or revenue perspective.

Ed: Okay.

Ed: Okay.

Speaker Change: Great and then just lastly can you just remind us sort of your expectations for <unk>.

Speaker Change: The behavioral health is going to be greater than the metabolic I think that eventually when we're looking on the average revenue per user the metabolic as loud Joe in terms of revenue.

Charles Rhyee: I think that eventually, when we are looking on the average revenue per user, the metabolic is larger in terms of revenue. Great.

Reaching breakeven is it still a year end of this year just wanted to just confirm that.

Speaker Change: Okay great.

Erez Raphael: And then just lastly, can you just remind us sort of your expectations for, you know, reaching breakeven? Is it still year-end of this year? Just wanted to just confirm that. Yes, operational break-even run rate. By the end of this year, this is going to be the objective. Just to your point on the 35%, I think that in the previous call, we talked about 35% growth in the total accounts that we are winning. And this year, this call, we updated the number that is going to be 50% growth in the total number of accounts. So we want to go by at least another 50 this year.

Speaker Change: Yes operational operational breakeven run rate by the end of this year. This is going to be the objective just to your point.

Speaker Change: Great and then just lastly can you just remind us sort of your expectations for reaching.

Speaker Change: Reaching breakeven is it still.

Speaker Change: On the 35% I think that in the previous call, we talked about 35% growth in the total accounts that we are winning and this year. This.

Speaker Change: Year end of this year just wanted to just confirm that.

Speaker Change: Yes, it's operational.

Speaker Change: Additional a breakeven run rate by the end of this year. This is going to be the objective just to your point on.

Speaker Change: This quarter, we updated the number of it is going to be 50% growth in the total number of accounts. So we want to go by at least another 50 accounts this year.

Speaker Change: The 35% I think that in the previous call, we talked about 35% growth in the total accounts that we are winning and this year. This.

Speaker Change: So that's the.

Speaker Change: <unk> that we had with the market.

Speaker Change: This quarter, we updated the number of it is going to be 50% Gulf in the total number of accounts. So we want to go by at least another 50 accounts this year.

Speaker Change: Understood. Okay. Thanks for the clarification I appreciate it.

Speaker Change: Yes, absolutely.

Speaker Change: <unk>.

Charles Rhyee: So that's the communication that we had with the market. Understood.

Speaker Change: Your next question comes from Ashok Kumar with think equity your line is now open.

Speaker Change: So that's the communication that we had was the market.

Speaker Change: Understood. Okay. Thanks for the clarification I appreciate it.

Charles Rhyee: Okay. Thanks for the clarification. Appreciate it. Yes, absolutely. Thank you.

Alright, Thank you Erez and Steven.

Speaker Change: Just a big picture questions in piece of flesh out any sub topics that would be of interest to investors.

Speaker Change: Yes, absolutely thank.

Speaker Change: Thank you.

Ashok Kumar: Your next question comes from Ashok Kumar with Think Equity. Your line is now open. Thank you, Erez and Steven. Just big picture questions and please flesh out any subtopics that would be of interest to investors. Again, the first question. is again from a business perspective, right?

Speaker Change: Your next question comes from Ashok Kumar with think equity your line is now open.

Speaker Change: The first question.

Speaker Change: And again from a business perspective, right how significant.

Speaker Change: Alright, Thank you Erez and Steven.

Ashok Kumar: Just a big picture questions and piece of flesh out any subtopics it would be of interest to investors.

Speaker Change: Do you see the role of <unk> treatments.

Speaker Change: Our strategy and growth opportunities.

Speaker Change: And two as digital.

Speaker Change: Again, the first question.

Speaker Change: Continues to evolve.

Speaker Change: Again from a business perspective, right how significant.

Speaker Change: What differentiates your business model and financial profile.

Ashok Kumar: How significant do you see the role of GLP-1 treatments in your strategy and growth opportunities? And two, as digital health continues to evolve. What differentiates your business model and financial profile? And how do these factors position the company for long-term profitability? Thank you. Thank you so much.

Speaker Change: Do you see the role of <unk> treatments.

Speaker Change: And how do these factors position.

Speaker Change: <unk> growth opportunities.

Speaker Change: The company for long term profitability. Thank you.

Speaker Change: In Q.

Speaker Change: Digital continues to evolve.

Speaker Change: Thank you so much.

Speaker Change: What differentiates your business model and financial profile.

Speaker Change: Maybe I'll start with the second with.

Speaker Change: With the second question.

Speaker Change: And how do these factors position.

Speaker Change: We have seen digital health company is evolving.

Speaker Change: The company for long term profitability. Thank you.

Speaker Change: But I think that when we are looking into the market and the valuations and soon.

Speaker Change: Thank you so much so.

Erez Raphael: So maybe I'll start with the second question. We have seen digital health companies evolving. But I think that when we are looking into the market and the valuations and so on, there was a general disappointment about the financial profile of these companies, their ability to build a viable business. And I think that here, the way that we designed our product offering, and also the way that we designed the organization is that we are building the business toward profitability. And the differentiator is number one in the ability to drive outcomes per patient. And number two is by helping our employers, specifically those that are 3,000, 5,000, 10,000 employees, to sign up on a full suite is something that is much more cost effective for them.

Speaker Change: Maybe I'll start with the second with.

Speaker Change: General disappointment about the financial profile of these companies the ability to build.

Speaker Change: With the second question.

Speaker Change: We have seen digital health companies evolving.

Speaker Change: <unk> business and I think that here.

Speaker Change: But I think that when we are looking into the market and the valuations and soon.

Speaker Change: The way that we designed.

Speaker Change: General disappointment about the financial profile of these companies the ability to build.

Speaker Change: Our product offering and also the way that we designed the organization is that.

Speaker Change: We are building the business toward profitability.

Speaker Change: Liable business and I think that here.

Speaker Change: Yeah.

Speaker Change: The way that we designed.

Speaker Change: The differentiator always number one and the ability to drive outcomes for patients.

Our product offering and also the way that we designed the organization is that fair.

Speaker Change: And then number two is by.

Speaker Change: We are building the business toward profitability.

Helping all of them.

Speaker Change: <unk> specifically those that are 3000, 5000, 10000 employees to sign up on our full suite.

Speaker Change: Yeah.

Speaker Change: The differentiator always number one and the ability to drive outcomes for patients.

Speaker Change: And that is a much more cost effective for them and it's also a cost effective for us.

Speaker Change: And then number two is by.

Speaker Change: Helping out there.

Speaker Change: Eventually we are generating between four to five small dollars, but everybody accounted for rail signing on so if you are combining this capability with a very strong engagement capability eventually youre looking into very high.

Speaker Change: Lawyers, specifically those that are 3000, 5000 10000 employees to sign up on our full suite.

Speaker Change: And that is much more cost effective for them and it's also a cost effective for us.

Erez Raphael: And it's also cost effective for us. So eventually, we are generating between four to five X more dollars for every account that we are signing on. So if you are combining this capability with a very strong engagement capability, eventually, you're looking into a very high revenue in ROI that we are getting for every account that we are signing on. And if you combine it with a very effective cost management, we showed how on an integrated base, we took the cost between Q1 to Q4 down by 35%. This trend is going to continue into 2025. We think that by Q4 of 2025, we're going to cut it by another 20%.

Speaker Change: Eventually we are generating between four to five small dollars, but every account that we are signing on so if you are combining this capability with a very strong engagement capability eventually looking into very high.

Speaker Change: Revenue in LOI that we are getting for every account that we are signing on and if you're combining with a very effective there.

Cost management, we showed how on an integrated basis, we took the cost between Q1 Q2 Q4 done by 35%. This trend is going to continue into 2025, we think that by Q4 2025, we're going to cut it by another 20%. So I think that's a very effective cost management.

Speaker Change: Revenue in LOI that we are getting good hopefully account that we are signing on and if you combine it with a very effective there.

Speaker Change: Cost management, we showed how long an integrated base. We took the cost between Q1 Q4 to Q4 done by 35%. This trend is going to continue into 2025, we think that by Q4 2025, we're going to cut it by another 20%. So I think that's a very effective cost management.

Speaker Change: Plus very engaging product plus very very.

Speaker Change: Our strong unit economics, when it comes to an account and also to a user that is something that puts us in a position that we are that we are going to create.

Erez Raphael: So I think that a very effective cost management plus very engaging product plus very, very strong unit economic when it comes to an account and also to a user, that's something that puts us in a position that we are going to create probably one of the first viable businesses in digital health.

Speaker Change: Plus very engaging product plus very very.

Speaker Change: Probably one of the first viable businesses and digital health.

Speaker Change: Our strong unit economics, when it comes to an account and also to a user that is something that puts us in a position that we are that we are going to probably one of the first viable businesses in digital health.

Speaker Change: So this one is regarding your second question.

Speaker Change: Getting back to your first question about the DLP won the.

Speaker Change: The two major trends that we see now that theyre going to push the revenue up and help us get there.

Erez Raphael: This one is regarding your second question. Getting back to your first question about the GLP-1, the two major trends that we see now that are going to push the revenue up and help us get a more significant portion in the market is number one, the fact that our clients are looking into more whole solution and whole person solution like multi-condition. That's number one. And number two is the continuous adoption of GLP-1. If you're looking into all the surveys that have been done among employers, you're going to see that the largest expense is on the GLP-1 drugs.

Speaker Change: Most significant portion in the market is number one the fact that our clients are looking into more whole solution and whole personal solution like multi condition. That's number one and number two is the continuous adoption of DLP, one if youre looking into the.

Speaker Change: This one is regarding your second question getting back to your first question about the DLP won.

Speaker Change: The two major trends that we've seen now that theyre going to push the revenue up and help us get there.

Speaker Change: Most significant portion in the market is number one the fact that they are clients are looking into more whole solution and whole person solution like multi condition. That's number one and number two is the continuous adoption of DLP. One if you are looking into the.

Speaker Change: All the surveys that have been done among employers youre going to see that.

Speaker Change: And the largest expense is on the <unk> one drugs in this whole thing needs to be managed in a way that they can.

Speaker Change: All the surveys that have been done among employers youre going to see that.

Speaker Change: Eventually get the most.

Speaker Change: <unk>.

Speaker Change: Uh-huh alloy from deploying these blogs and this is something exactly what we can help them doing and we can help them show an immediate cost reduction ones, though.

Speaker Change: And the largest expense is on the <unk> one drugs in this whole thing needs to be managed in a way that they can.

Erez Raphael: And this whole thing needs to be managed in a way that they can eventually get the most effective ROI from deploying these drugs. And this is something exactly what we can help them doing. And we can help them show an immediate cost reduction once they're adopting us. It's for GLP-1 and also for the other conditions that we are running. So we think that the GLP-1 is going to be a larger and larger portion of the revenue that we're going to generate this year and the year after. We already signed 10 accounts last year, and this year we think that we're going to at least double it when it comes to GLP-1.

Speaker Change: Eventually get the most effective there.

Speaker Change: Now are adopting us.

Speaker Change: It's full GMP, one and also for the other.

Speaker Change: Oh why from deploying these blogs and this is something exactly what we can help them doing and we can help them show an immediate cost reduction once.

Speaker Change: For the other conditions that prevail lending. So we think that the <unk> is going to be.

Speaker Change: A larger and larger portion of the book.

Speaker Change: Now are adopting us.

Speaker Change: The revenue that we're going to generate.

Speaker Change: It's for Q1 and also for the other.

Speaker Change: This year in the year after.

Speaker Change: For the other conditions that prevail lending. So we think that the <unk> is going to be.

Speaker Change: We already signed 10 accounts last year and this year, we think that we go ahead. Please don't believe when it comes with GMP, one and that one is going to be large in terms of the revenues as well.

Speaker Change: A larger and larger portion of the book.

Speaker Change: Revenue that we're going to generate.

Speaker Change: This year in the off too.

Eric: And Eric if I could add.

Speaker Change: We already signed 10 accounts last year and this year, we think that we go to at least double it when it comes to <unk>, one and that one is going to be large in terms of the revenues as well.

Speaker Change: I'd add just to your question in terms of the strategic moat.

Speaker Change: So areas covered where we are in terms of a company being mindful profitable et cetera. That's our goal where we're stated were at run rate et cetera.

Erez Raphael: And that one is going to be large in terms of the revenues as well.

Steven Nelson: And Erez, if I could add, you know, what I'd add just to your question in terms of the strategic moat. So Erez covered where we are in terms of a company being mindful, profitable, etc. That's our goal, where we're stated, where we're at, run rate, etc. On target, want to execute there. Two, outline what we have, differentiate around GLP-1 to pivot. We have D2C kind of, you know, helping us, our business model, understand where we go and how we go as well. And then we also have learning from that to enable our B2B2C business. And that is a differentiator.

Eric: And Eric if I could add.

Speaker Change: On target when to execute their two.

Eric: What I'd add just to your question in terms of the strategic moat.

Speaker Change: Outline what we have differentiator around G. L. P. One to pivot we.

Eric: So areas covered where we are in terms of a company being mindful profitable et cetera. That's our goal where we're stated were at run rate et cetera.

Speaker Change: We have D to C kind of.

Speaker Change: Helping us our business model understand where we go and how we go as well and then we also have learning from that to enable our <unk> business and that is a differentiator.

Eric: On target when to execute their two.

Eric: Outlined what we have differentiator around G. L. P wanted to pivot we.

Speaker Change: We learned from that market. We then take it to the market hardened better et cetera that is a differentiator, we can leverage that data and those experiences to make our product more viable for the areas in wholesale distribution employers health plans et cetera. So we have a good learning ground.

Eric: We have D to C kind of you know.

Eric: Helping us our business model understand where we go and how we go as well and then we also have learnings from that to enable our <unk> business and that is a differentiator.

Steven Nelson: We learn from that market. We then take it to the market, hardened, better, etc. That is a differentiator. We can leverage that data and those experiences to make our product more viable for the areas in wholesale distribution, employers, health plans, etc. So we have a good learning ground. Another strategic moat goal is being multi-conditioned. We have to harness that. And the more we can harness that as a responsible company, in terms of being mindful of how we grow and where we grow as a profitable entity, having other areas we can grow, our multi-conditioned platform as we grow and scale, it's a strategic moat for us.

Eric: We learned from that market. We then take it to the market hardened better et cetera that is a differentiator, we can leverage that data and those experiences to make our product more viable for the areas in wholesale distribution employers health plans et cetera. So we have a good learning ground.

Speaker Change: Another strategic Melco is being multi multi condition.

Speaker Change: We have to harness that.

Speaker Change: And the more we can harness that as a responsible company.

Speaker Change: In terms of being mindful of how we grow and where we grow as a profitable entity.

Eric: Another strategic Melco is being multi multi condition.

Speaker Change: Having other areas, we can grow our multi condition platform as we grow and scale, it's a strategic move for us and the market starting to meet us there.

Eric: We have to harness that.

Eric: And the more we can harness that as a responsible company.

Eric: In terms of being mindful of how we grow and where we grow as a profitable entity.

Speaker Change: I think so theres a lot around digital health for that as well, but we can add value to them partner solution integrate with other partners just like we announced we.

Eric: Having other areas, we can grow our multi condition platform as we grow and scale, it's a strategic move for us and the market starting to meet us there.

Speaker Change: We don't have to build it all ourselves we can find other partners to bring it in and make sure that our multi solution multi conditioning platform.

Steven Nelson: And the market's starting to meet us there. I think so there's a lot around digital health for that as well. But we can add value to them, partner, solution, integrate with other partners, just like we announced. We don't have to build it all ourselves. We can find other partners to bring it in and make sure that our multi-solution, multi-conditioned platform is viable for all of our three target segments in ways that helps their business.

Eric: I think so theres a lot around digital health for that as well, but we can add value to them partner solutions integrate with other partners just like we announced.

Speaker Change: Viable for all of our three target segments in ways that helps their business. So just to kind of round that out in terms of the boat. If you will because you asked about where we stand strategic differentiation I think just for clarity that's being responsible towards our business model for sure but in terms of the market. It's converting what we do need to see to be the BDC and its having multi condition.

Eric: Don't have to build it all ourselves we can find other partners to bring it in and make sure that our multi solution multi conditioning platform is viable for all of our three target segments in ways that helps their business. So just to kind of round that out in terms of the boat. If you will because you asked about where we stand strategic differentiation I think just for clarity that's being responsible towards our business.

Unknown Executive: So just to kind of round that out in terms of the moat, if you will, because you asked about where we stand in strategic differentiation. I think just for clarity, it's being responsible towards our business model, for sure. But in terms of the market, it's converting what we do D to C to B to B to C, and it's having multi-condition to really go to the market. Thank you, Erez and Steven, all the best. Thank you. Thank you, Ashok. Ladies and gentlemen, as a reminder, should you have a question, please press star 1.

Speaker Change: Go to the market.

Speaker Change: Okay. Thank you soon all the best.

Speaker Change: Thank you. Thank you sure.

Eric: Model for sure but in terms of the market, it's converting what we do D to C to be the BDC and its having multi condition.

Speaker Change: Ladies and gentlemen, as a reminder, should you have a question. Please press star one.

Eric: To really go to the market.

Speaker Change: Okay.

Eric: Okay. Thank you soon all the best.

Speaker Change: Your next question comes from David Grossman with Stifel. Your line is now open.

Eric: Thank you. Thank you sure.

Speaker Change: Ladies and gentlemen, as a reminder, should you have a question. Please press star one.

David Grossman: Thanks, Good morning, Thank you.

Eric: Okay.

Speaker Change: No.

Eric: Okay.

Speaker Change: Erez you spoke several times about vendor consolidation.

Eric: Yeah.

David Grossman: Your next question comes from David Grossman with FIFO. Your line is now open. Good morning. Thank you. You know, Erez, you spoke several times about vendor validation.

Speaker Change: Your next question comes from David Grossman with Stifel. Your line is now open.

Speaker Change: Perhaps you could share some statistics on the trends.

Speaker Change: Customers, taking multiple bolt.

David Grossman: Thanks, Good morning, Thank you.

Speaker Change: Whether that'd be metabolic taking behavior or vice versa or <unk>.

Speaker Change: Erez you spoke several times about vendor consolidation.

Erez Raphael: You know, perhaps you could share some, you know, statistics on the trends in customers taking multiple solutions, you know, whether that be metabolic, taking behavioral, vice versa, or GLP-1. Yeah, so. So when we are talking about multi-condition, it's not necessarily both metabolic and behavioral health. You have like clients that are taking diabetes and also hypertension and also weight loss. I would say that today more than 50 percent of the accounts that we are signing on are taking more than one condition. Okay, that's something that we're already seeing. It's a very strong trend, and most of it is in the metabolic.

Speaker Change: Perhaps you could share some statistics on the trends.

Speaker Change: Yes.

Speaker Change: Yeah.

Speaker Change: So when we are talking about winter condition.

Speaker Change: Customers, taking multiple solutions.

Speaker Change: Necessarily there both metabolic and be able health do you have like clients without taking.

Speaker Change: Whether that'd be metabolic taking behavior or vice versa or GLC ones.

Speaker Change: Diabetes and upside potential and also worthless.

Speaker Change: Yeah. So we're.

Speaker Change: I'd say that.

Speaker Change: So when we are talking about won't be condition is not necessarily the both metabolic and be able health do you have like clients that theyre taking.

Speaker Change: Today.

Speaker Change: More than 50% of the accounts that we are signing are thinking more than one condition. Okay.

Speaker Change: That's something that.

Speaker Change: Diabetes and upside potential and also weightless I would say that.

Speaker Change: And that will be.

Speaker Change: Seeing it's a very it's a very strong trend and most of it is in.

Speaker Change: Today.

Speaker Change: More than 50% of the accounts that we are finding or thinking more than one condition. Okay.

Speaker Change: The metabolic and those that are thinking diabetes, and hypertension hypertension and weight loss and I'll discuss.

Speaker Change: That's something that.

Speaker Change: And that we're already seeing it's a very it's a very strong trend and most of it is in the.

Speaker Change: This kind of stuff.

Speaker Change: When it comes to full suite.

Speaker Change: All of the metabolic.

Speaker Change: The metabolic and those that are picking diabetes, and hypertension hypertension and weight loss and I'll discuss this.

Erez Raphael: Those that are taking diabetes and hypertension, hypertension and weight loss and all this kind of stuff. When it comes to full suite, Dario, all the metabolics, plus the behavioral health, at the moment we don't have any account that bought this full suite on an integrated base. And we need to remember that we integrated the product only in 2020-2024, and everything is under the same brand as of Q4 of 2024. We do have clients that were signing on the behavioral health and are now in a very, very advanced process to take also the metabolic, and we have those that are on the metabolic that are also taking the behavioral health solution.

Speaker Change: Plus there'll be able health at the moment, we don't have any accounts.

Speaker Change: This kind of stuff.

Speaker Change: Both this full suite.

Speaker Change: When it comes to full suite.

Speaker Change: On an integrated basis, and we need to remember that we integrated the product only in 2020.

Valeo.

Speaker Change: All of the metabolic.

Speaker Change: Plus the behavioral health at the moment, we don't have any accounts.

Speaker Change: 2020, full and everything is under there is under the same brand as of Q4 2024.

Speaker Change: Both this full suite.

Speaker Change: On an integrated basis, and we need to remember that we integrated the products only in 2020.

Speaker Change: We do have clients that were signing on do you have a lot here.

Speaker Change: And I will now and are very very advanced process to take also the metabolic and we have those that are under Mr. <unk> also thinking there'll be able unhealthy solution and thats something that we see.

Speaker Change: 2020, full and everything is under there is under the same brand as of Q4 2024.

We do have clients that were signing on the overall health and are now in a very very advanced process to take also the metabolic and we opened those that are under metabolic. It at the also taking there'll be able unhealthy solution and thats something that we see.

Speaker Change: As will happen this year will allow the count at least three to five times. This is the statistic that we expect we think that in order to sell the full suite in one shot.

Erez Raphael: And that's something that we see as will happen this year with loud accounts at least three to five times. This is the statistic that we expect. We think that in order to sell the full suite in one shot, like both all the metabolic plus the behavioral health to one client, we think that it's going to be easier when we are looking into the employer size that is between 2,500 employees to 10,000 or 15,000 employees, and this is something that we expect that will happen this year because we already see all the RFPs and all the demand that is coming in.

Speaker Change: Jack.

Speaker Change: Both of them at the embolic, plus there'll be able health to one clients, we think that it's going to be easier. When we are looking into the employer size that is between 2500 employees 210, or 15000 employees and this is something that we expect that would happen this year.

Speaker Change: As will happen. This year was allowed to count at least three to five times. This is the statistic that we expect we think that in order to sell the full suite in one shot.

Speaker Change: Jack.

Speaker Change: Both of them at the Bullock, plus there'll be able health to one client we think that it's going to be easier. When we are looking into the employer size that is between 2500 employees to 10 or 15000 employees and this is something that we expect that will happen this year.

Speaker Change: We already are.

Speaker Change: I see all the other fees and all the demand that is coming in.

Speaker Change: I think that eventually if I'm going to look into a potential 50 wins this year.

Speaker Change: That's at least a third of them are going to be for the full suite and I think that from the existing clients that we have with the allowance cloud clients as I said, we're going to win between three to five accounts.

Speaker Change: We already are.

Speaker Change: I see all the other fees and all the demand that is coming in.

Erez Raphael: So I think that eventually, if I'm going to look into a potential 50 wins this year, I think that at least a third of them are going to be for the full suite. And I think that from the existing clients that we have that are large clients, as I said, we're going to win between three to five accounts that are going to cost sale on a single condition into a full suite. We don't think that the huge, you know what? There is one exception.

Speaker Change: I think that eventually if I'm going to look into a potential 50 wins this year.

Speaker Change: On the cross sell.

Speaker Change: <unk> syndrome condition into input full suite.

Speaker Change: That's at least a third of them are going to be for the full suite and I think that from the existing clients that we have allowed them to cloud clients as I said, we're going to win between three to five accounts.

Speaker Change: We don't think that the huge.

Speaker Change: There is one exception we are working on are really very very large client mission on health plan that theres going to thinking one chubb the entire full sweep that expectation.

Speaker Change: On the cross sell.

Speaker Change: It seems and conditioning to input full suite.

Speaker Change: We don't think that the huge.

Speaker Change: And that we have for the next few months, but that's in general on the statistic that we have we don't think that we're going to see.

Speaker Change: You know what there is one exception we are working on are really very very large client mission on health plan that theres going to thinking one chubb the entire full suite that's the expectation.

Charles Rhyee: We are working on a very, very, very large client, National Health Plan, that is going to take in one shot the entire full suite. That's the expectation that we have for the next few months. But that's in general the statistic that we have. We don't think that we're going to see large accounts that are like hundreds of thousands of users like health plans that are going to take everything in one shot. The statistic there is going to be more gradual. They're going to sign up on a single condition and then expand into more conditions. Thanks for that clarification.

Speaker Change: Large accounts that I would like hundreds of thousands of users like a health plan.

Speaker Change: Everything in one shot this statistic is going to be more gradual and they're going to sign up on our single condition and then expanding more conditions.

Speaker Change: And that we have for the next few months, but that's in general in the statistics that we have we don't think that we're going to see.

Speaker Change: Large accounts that I would like hundreds of thousands of users like our health plans.

Speaker Change: Got it alright, thanks for that clarification.

Speaker Change: Just going back also to your comments.

Speaker Change: Everything in one showed the statistic is going to be more gradual they're going to sign up on our single condition and then expanding to more conditions.

Speaker Change: About some of the strategic relationships with large pharma.

Speaker Change: Perhaps you could update us on the status.

Speaker Change: Let's see.

Speaker Change: Got it alright, thanks for that clarification so.

Erez Raphael: So just going back also to your comments about some of the strategic relationships with large pharma, you know, perhaps you could update us on the status of Sanofi and The other strategic relationships in the pipeline, are they primarily geared, what they're trying to do with GLP-1s and perhaps some more direct-to-consumer type relationships, or are the potential relationships broader or different than that? Yeah, so for Sanofi, we're very clear, both in the press release and also in the script, that the existing relationship that was more like clinical and data-oriented has been transformed to be more commercial-oriented.

Speaker Change: The other strategic relationships in the pipeline are they primarily geared.

Speaker Change: Just going back also to your comments.

Speaker Change: But they are trying to do with <unk> and perhaps some more direct to consumer type relationships or are the potential relationships broader or different than that.

Speaker Change: About some of the strategic relationships with large pharma.

Speaker Change: Perhaps you could update us on the status.

Speaker Change: Let's see.

Speaker Change: The other strategic relationships in the pipeline are they primarily geared.

Speaker Change: Yeah.

Speaker Change: Yes.

Speaker Change: Yes, so so so full for Santa Fe will very clearly both in the press release and also in the script.

And to do with <unk>, and perhaps some more direct to consumer type relationships or are the potential relationships broader or different to that.

Speaker Change: The existing relationship that was more like a <unk>.

Speaker Change: Yeah.

Speaker Change: Clinical and data oriented has been transform to be more commercial oriented.

Speaker Change: Yeah. So so so full full Santa Fe will really clear both in the press release and also on the script.

Speaker Change: And that's something that.

Speaker Change: I mean, the accounting and generate revenue.

Speaker Change: The existing relationship that was more like a clinical and data oriented has been transform to be more commercial oriented and that's something that.

Speaker Change: <unk> almost at all.

Speaker Change: And this year. It is going to is going to get back to revenues starting from Q1, because it's under a different commercial agreement. So we expect it will continue the revenue generation. This year just two.

Erez Raphael: And that's something that, I mean, the account didn't generate revenue last year almost at all. And this year it's going to get back to revenues starting from Q1 because it's under a different commercial agreement. So we expect it will continue the revenue generation this year. Just to remind the audience, when we are selling the TwilioCare or what we are calling today DarioConnect, it's a solution that we are selling to a pharma company that is helping them with the top of finance. And this is something that Sanofi selected for one of the drugs. And that's something that has been launched and generating revenue starting from Q1.

Speaker Change: I mean the.

Speaker Change: The account didn't generate revenue last year almost at all and we said, it's going to it's going to get back to revenues starting from Q1, because it's under.

Speaker Change: To remind the audience when we are selling.

Speaker Change: Yeah.

Speaker Change: Yes.

Speaker Change: A different commercial agreement. So we expect it will continue the revenue generation this year just two.

Speaker Change: What we are calling today value of connect.

Speaker Change: The solution that we're selling for pharma company that is helping them with the top of funnel and this is something that Sanofi selected for one of the.

Speaker Change: To remind the audience when we are selling.

Speaker Change: The.

Speaker Change: Drugs and Thats something that has been launched and generating revenue starting from Q1. So this account has been transformed.

Speaker Change: The food and tell what we are calling today valuable connect it's a solution that we're selling to pharma company that is helping them with the top of funnel and this is something that the Sanofi selected for one of them though.

Speaker Change: When we acquired <unk>.

Speaker Change: They had such that some agreements with pharma companies with well conforming is win so we're going to see this film Shannon generating recurring revenue is something that would happen.

Speaker Change: Drugs and that's something that has been launched and Janet I think revenue starting from Q1. So this accounts has been transformed.

Erez Raphael: So this account has been transformed. When we acquired Twilio, they had some agreements with pharma companies that we are transforming as well. So we're going to see this pharma channel generating recurring revenue, something that will happen this year after last year was almost zero in terms of pharma because we were transforming everything into a recurring revenue model.

Speaker Change: When we acquire when they had such a there is some agreement with pharma companies that will conforming is win so we're going to see this film Shannon generating recurring revenue is something that would happen.

Speaker Change: It would have been.

Speaker Change: This year after the last year was almost zero in terms of pharma, because we will transforming everything into a recurring revenue model.

Speaker Change: So that's with regards to <unk>.

Speaker Change: It would have been.

Speaker Change: So sanofi the other things that we expect is that.

Speaker Change: This is after last year was almost zero in terms of pharma, because we will transforming everything into a recurring revenue model.

Speaker Change: And that's something that is there.

Very important for us to stabilize the revenue in a way that we are.

Erez Raphael: So that's with regards to Sanofi. The other thing that we expect is that that's something that is very important for us to stabilize the revenue in a way that we are more predictable. And I think that if we're looking like one or two years back, we had like a situation that single or two accounts were contributing like 70% or 50% of our B2B revenues. We expect that in 2025 we're going to change it and more broadly in 2026 because we're going to sign more accounts. We're going to see accounts that are more coming from employers.

Speaker Change: So that's with regards to to Sanofi and the other things that we expect is that the.

Speaker Change: More predictive than anything that if we are looking like one or two years back we had like a situation that single or two accounts with contributing like 70% to 50% of <unk> revenues.

Speaker Change: And that's something that is very important for us to <unk>.

Speaker Change: The revenue in a way that we are well more predictable and it seems that if we are looking like one or two years back we had like a situation that single or two accounts.

Speaker Change: We expect this in 2025, we're going to change it and more broadly in 2026.

Speaker Change: We then assign more accounts, we're going to see accounts of the thermal area.

Speaker Change: Debuted thing like a 70% to 50% of <unk> revenues.

Speaker Change: The thermal coming from employers and Thats something that will.

Speaker Change: We expect that in 2025, we're going to change it more broadly in 2026, because we then assign moly pounds were going to see accounts that are more.

Speaker Change: This will help us there.

Speaker Change: Stabilize.

So making the revenue is much more predictable.

Speaker Change: We do have a few large relationships that we are working on.

Speaker Change: The thermal coming from employers and Thats something that will.

Erez Raphael: And that's something that will help us stabilize or make the revenues much more predictable.

Speaker Change: We think that two or three of them are going to be signed this year. One of them is a national health plan to trim that when I think of the full suite.

Speaker Change: He will help us there.

Speaker Change: So making the revenues much more predictable.

Speaker Change: But the majority of the revenue is going to start then come format from a relatively weak.

Erez Raphael: We do have a few large relationships that we are working on. We think that two or three of them are going to be signed this year. One of them is a national health plan that's going to take the full suite. But the majority of the revenue is going to start and come from a relatively small to medium account. So we're going to see a lot of accounts that are somewhere between $300,000 to $1.5 million. Most of them are employers.

Speaker Change: We do have a few large relationships that we are working on.

Speaker Change: We think that two or three of them are going to be signed this year. One of them is a national health plan to trim.

Speaker Change: Small to medium accounts, so we're going to see a local if it comes about somewhere between $300000 to $1 5 million.

Speaker Change: To take the full suite.

Speaker Change: But the majority of the revenue is going to start then come for me from a relatively weak.

Speaker Change: Most of them are employers.

Speaker Change: Got it and just one last thing I think in your prepared remarks you.

Speaker Change: Small to medium accounts, so we're going to see a lot of it comes about somewhere between $300000 to $1 $5 million at.

Speaker Change: Explained you talked a little bit about tying pricing results and client based billing can you just explain that.

Speaker Change: Most of them are employers.

Charles Rhyee: Got it.

Speaker Change: Got it and just one last thing I think.

Steven Nelson: And just one last thing. I think in your prepared remarks, you explained or you talked a little bit about tying pricing to results and claim-based billing. Can you just explain that or go into a little more detail on what you meant by that?

Speaker Change: Or go into a little more detail on what you meant by that.

Speaker Change: Yeah, I'll take that one.

Speaker Change: Your prepared remarks you.

Speaker Change: Two things one is that.

Speaker Change: Explained you talked a little bit about tying pricing that results in client based billing can you just explain that.

Speaker Change: Today.

Speaker Change: We dial in terms of our product mix being build out to the market.

Speaker Change: Or go into a little more detail on what you meant by that.

Speaker Change: We only have a certain percentage that we had actually process in terms of a claim.

Steven Nelson: Yeah, I'll take that one. Two things. One is that today, We, Dario, in terms of our product mix being billed out to the market, we only have a certain percentage that we actually process in terms of a claim. And now we're allowing our clients, which would be employers or health plans, we're ramping up the ability so it could be paid as a claim. Today our services are paid out of the administration side of the house. Majority of all of our programming is paid for from health plans or from employers through the admin side of their budget.

Yeah, I'll take that one too.

Speaker Change: Two things one is that today.

And now, we're allowing our plant our clients, which would be employers or health plans, we're ramping up the ability. So it could be paid as a claim today. Our services are paid out of the administration side of the house majority of all of our programming is paid for from health plans or from employers through the admin side of their budgets.

Speaker Change: We Dario in terms of our product mix being build out to the market.

Speaker Change: We only have a certain percentage that we had actually process in terms of a claim.

Speaker Change: And now, we're allowing our our clients, which would be employers or health plans, we're ramping up the ability so that could be paid as a claim today. Our services are paid out of the administration side of the house majority of all of our programming is paid for from health plans or from employers through the admin side of their budgets.

Speaker Change: We're now moving to aside to enhance our billing options to get involved with the claim based side of the budgets and I don't want to get into the all of it here on the call, but I'm sure as many of you know there was the claims side of the equation and the admin side of the equation. When you look at health insurance and now we're starting to play towards the claim side.

Steven Nelson: We're now moving to a side to enhance our billing options to get involved with the claim-based side of the budgets. And I don't want to get into all of it here on the call, but I'm sure as many of you know, there is the claim side of the equation and the admin side of the equation when you look at health insurance. And now we're starting to play towards the claim side of the equation, using that data to help us target better, engage more, report out, and I'd say get to the last thing which I'll come to now, which is the outcomes.

Speaker Change: We're now moving to aside to enhance our billing options to get involved with the claim based side of the budgets and I don't want to get into all of it here on the call, but I'm sure as many of you know there was the claims side of the equation and the admin side of the equation. When you look at health insurance and now we're starting to play towards the claim side.

Speaker Change: Of the equation using that data to help us target better engage more report out and I'd say get to the last thing, which I'll come to know which is the outcomes we need to look at the claims.

Speaker Change: There's a lot we can do to tie our programming simpler to existing clinical milestones that the employee needs to meet and when they meet that clinical milestone then we get paid it's really a way for us to partner a lot more around our product in a direct way that shows the impact.

Speaker Change: <unk> of the equation using that data to help us target better engage more report out and I'd say get to the last thing, which I'll come to know which is the outcomes we need to look at the claims.

Steven Nelson: We need to look at the claims. There's a lot we can do to tie our programming simpler to existing clinical milestones that the employee needs to meet. And when they meet that clinical milestone, then we get paid. It's really a way for us to partner a lot more around our product in a direct way that shows the impact. And so for us, it's kind of a good way to kind of turn another option to engage people. We have one of those already in market today with the health plan. And we are discussing how and where we roll those out to other health plans and or discussing how and where we roll those that pricing model out specifically to employers.

Speaker Change: There's a lot we can do to tie our programming simpler to existing clinical milestones that the employee needs to meet and when they meet that clinical milestone then we get paid it's really a way for us to partner a lot more around our product in a direct way that shows the impact.

Speaker Change: So for US, it's kind of a good way to kind of turn another option to engage people.

Speaker Change: We have one of those already in market today with the health plan and we are discussing how and where we roll those out to other health plans <unk> discussing how and where we roll those that pricing model out specifically to employers.

Speaker Change: And so for US it's kind of a good way to kind of turn another option to engage people.

Speaker Change: We have one of those already in market today with the health plan and we are discussing how and where we roll those out to other health plans <unk> discussing how and where we roll those that pricing model out specifically to employers.

Speaker Change: And I think both of those are going to be a little bit differentiated and what's in the market today from a pricing perspective without going into all the details. We think we can win there so to recap getting more on the claims side of the equation for both targeting analyzing and processing ourselves in terms of us receiving revenue that's important too and then secondary.

Steven Nelson: And I think both of those are going to be a little bit differentiated than what's in the market today from a pricing perspective without going into all the details. We think we can win there. So to recap, getting more on the claims side of the equation for both targeting, analyzing and processing ourselves in terms of us receiving revenue, that's important too. And then secondarily, getting closer using that claims, claims basis, claims knowledge, get closer to outcomes, which can also tie to like, without getting into a value based payments, value based payment models, etc. So differentiation and ease of business and differentiation on how we can get after a revenue pool for ourselves.

Speaker Change: And I think both of those are going to be a little bit differentiated and what's in the market today from a pricing perspective without going into all the details. We think we can win there so to recap getting more on the claims side of the equation for both targeting analyzing and processing ourselves in terms of us receiving revenue that's important too and then secondary.

Speaker Change: Really getting closer or using that claims claims basis claims knowledge get closer to outcomes, which can also tie to like without getting into a value based payments value based payment models et cetera. So differentiation in the ease of business and differentiation on how we can get after a bigger revenue pool for ourselves as well.

Speaker Change: Really getting closer using that claims claims basis claims knowledge get closer to outcomes, which can also tie to like without getting into a value based payments value based payment models et cetera, so differentiation and ease of business and differentiation on how we can get after a bigger revenue pool for ourselves as well.

Speaker Change: Got it thanks very much good luck.

Speaker Change: You bet. Thank you thank.

Dave: Thank you Dave.

Speaker Change: There are no further questions at this time, ladies and gentlemen. This concludes your conference call for today, we thank you for participating and ask that you. Please disconnect your lines.

Unknown Executive: Thanks very much. Good luck. Yvette, thank you. Thank you, Dave.

Speaker Change: Got it thanks very much good luck.

Speaker Change: You bet. Thank you thank.

Dave: Thank you Dave.

Speaker Change: Yeah.

Unknown Executive: There are no further questions at this time.

Speaker Change: There are no further questions at this time, ladies and gentlemen. This concludes your conference call for today, we thank you for participating and ask that you. Please disconnect your lines.

Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.

Speaker Change: Yes.

Speaker Change: Okay.

Speaker Change: [music].

Speaker Change: No.

Speaker Change: [music].